Bacterial imaging agents and methods of use thereof
Fluorescent imaging agents targeting bacterial and apoptotic cell surfaces provide rapid and sensitive detection of infections, addressing the limitations of existing methods and enhancing diagnostic precision.
Patent Information
- Application Number
- CN202111463705.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2012-03-30
- Filing Date
- 2013-03-15
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2033-03-15
AI Technical Summary
Current diagnostic methods for bacterial infections are time-consuming, insensitive, and unreliable, and anatomical imaging techniques like MRI and CT cannot distinguish between infection and sterile inflammation, limiting early detection and effective treatment.
Development of fluorescent imaging agents that bind to the anionic surfaces of bacteria and apoptotic cells, utilizing cationic moieties linked to fluorophores that emit in the far-red or near-infrared region for accurate in vivo imaging.
Enables rapid, sensitive detection and quantification of bacterial infections and apoptosis, improving diagnostic accuracy and therapeutic decision-making.
Smart Images

Figure BDA0003390373850000031 
Figure BDA0003390373850000041 
Figure BDA0003390373850000042
Abstract
Description
[0001] CROSS REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 61 / 618,291, filed March 30, 2012, the contents of which are incorporated herein by reference. Technical Field
[0003] The present invention provides compositions and methods for detecting bacteria in a subject. The compositions generally contain a bacteria targeting moiety and an imaging reporter, which can be a fluorophore. Background of the Invention
[0004] Current methods for assessing molecular endpoints in certain diseases typically require tissue and blood sampling, surgery, and in the case of experimental animals, sacrifice at different time points. Despite improvements in non-invasive imaging, more sensitive and more specific imaging agents and methods are still needed. Imaging techniques that can visualize specific molecular targets and / or entire pathways will significantly improve our ability to diagnose and assess the therapeutic effects of therapeutic interventions on many different disease states. Most current imaging techniques primarily report anatomical or physiological information (e.g., magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound). Newer modalities such as optical imaging and new molecular imaging probes have the potential to revolutionize the way to detect, treat, and monitor diseases.
[0005] Common paradigms for molecular imaging involve the use of "molecular" probes or agents that selectively target specific genes, proteins, receptors, or cellular functions, where the absence, presence, or level of a specific target is indicative of a particular disease state.
[0006] In particular, optical imaging provides several advantages, making it a powerful molecular imaging method in both research and clinical environments. Specifically, optical imaging can be fast, safe, cost-effective and highly sensitive. Scanning time is on the order of seconds to minutes, does not require ionizing radiation, and the imaging system can be relatively simple to use. In addition, optical probes can be designed to dynamic molecular imaging agents, which can change their reporting situations (profiles) in vivo to provide molecular and functional information in real time. In order to obtain maximum penetration and sensitivity in vivo, for most optical imaging in biological systems, select red and near infrared (NIR) spectral regions (600-900nm) within the range, although other wavelengths in the visible light region can also be used. In the NIR wavelength range, physiologically abundant absorbents such as the absorption of hemoglobin or water and the autofluorescence of tissues are reduced to a minimum.
[0007] Gram-negative and Gram-positive bacteria are the most common causes of infection, for example, periprosthetic, joint, bone, vascular prosthetic graft, groin, umbilical cord or incisional hernia patch infection, and are one of the challenging surgical complications. Conventional diagnostic methods that rely on analysis of cultured bacteria recovered from suspected sites are time-consuming, insensitive, and not always feasible. Anatomical imaging techniques such as MRI and CT cannot always distinguish between infection and sterile inflammation and are therefore unreliable. Recently, the use of radiolabeled antibiotics and peptides directed against specific organisms has been studied, but clinical use is limited, in part because of suboptimal specificity or sensitivity.
[0008] Early detection of bacterial infection is associated with a better prognosis for full recovery. The unique cellular architecture of bacteria provides a number of different means for detecting and marking sites of infection. The cell membrane, DNA, and cell wall are three well-studied bacterial structures. The cell surface of bacteria is highly negatively charged, much higher than that of healthy mammals. Positively charged cationic probes can be used to selectively target and bind to the anionic surface of bacterial cells compared to healthy mammalian cells.
[0009] Mammalian cells undergoing apoptosis, or programmed cell death, also exhibit a much higher negative charge than normal cells. In addition, positively charged cationic probes targeting bacteria or cells infected (compromised) by bacteria can also recognize and bind to unhealthy apoptotic mammalian cells.
[0010] Using such an approach, cationic molecules specific for anionic surfaces such as those present in bacteria and apoptotic cells can be linked to fluorescent molecules and used to probe sites / regions of bacterial infection and / or apoptosis.
[0011] The ability to more accurately and efficiently detect and quantify sites of bacterial infection and apoptosis will aid in the understanding of biological phenomena such as pathogenesis, infection, and cell death, and help determine the most appropriate therapeutic options. Brief description of the invention
[0012] The present invention provides a new class of fluorescent imaging agents that bind to the anionic surfaces of bacteria and apoptotic cells and can be used in a variety of in vitro and in vivo applications, including but not limited to the identification of bacterial cells, such as those found in microbial infections. Also provided are cationic agents / ligands that fluoresce in the far-red or near-infrared region, which are particularly useful for in vivo imaging of bacteria in living animals. In addition, agents are provided that independently contain far-red or near-infrared fluorophores that have been modified with a large number of chemical modifying groups that can be used to optimize the in vitro and in vivo properties of the agents.
[0013] In certain embodiments, the bacteria targeting agent comprises: a bacteria targeting moiety comprising a positively charged moiety optionally substituted with an aliphatic, aromatic or heteroaromatic moiety; and an imaging reporter, optionally chemically linked to the bacteria targeting moiety via a linker (L) moiety.
[0014] In certain embodiments, the positively charged component of the bacteria targeting agent is one of the following:
[0015]
[0016] Where n is 1, 2, 3, 4, 5, or 6.
[0017] In certain embodiments, the positively charged moiety is doubly positively charged and is represented by one of the following formulae:
[0018]
[0019] Where R 1 and R 2 is independently substituted or unsubstituted aryl, C 1 -C 18 In certain embodiments, R 1 and R 2 and R at each occurrence is independently substituted or unsubstituted heteroaryl.
[0020] In other embodiments, the bacteria targeting agent comprises: a bacteria targeting moiety comprising a positively charged 1,4-diazabicyclo[2.2.2]octane (DABCO) moiety optionally substituted with an aliphatic, aromatic or heteroaromatic moiety; and an imaging reporter, optionally chemically linked to the bacteria targeting moiety via a linker (L) moiety.
[0021] In certain embodiments, the imaging reporter is selected from the group consisting of a fluorescent moiety, a magnetic moiety, and a radioisotope. In addition, the imaging reporter carries a plurality of chemically modified moieties.
[0022] Another aspect of the present invention provides a compound of formula (I) or a salt thereof:
[0023]
[0024] where the variables are as defined in the detailed description.
[0025] Another aspect of the present invention provides a compound of formula (II) or a salt thereof:
[0026]
[0027] where the variables are as defined in the detailed description.
[0028] Another aspect of the present invention provides a compound of formula (III) or a salt thereof:
[0029]
[0030] where the variables are as defined in the detailed description.
[0031] In certain embodiments, the bacteria targeting agent (eg, a compound of Formula I, II, or III) fluoresces in the far-red or near-infrared wavelengths.
[0032] Another aspect of the present invention provides a compound of formula (IV) or a salt thereof:
[0033] F-(L) n -(Z) m
[0034] (IV)
[0035] where the variables are as defined in the detailed description.
[0036] In certain embodiments, the chemically modified moiety (M) is selected from hydrogen, alcohol, sulfonate, polysulfonate, cysteine, sulfonamide, sulfoxide, sulfone, carboxylate, ketone, phosphonate, phosphate, iminodiacetate, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, tetraazacyclododecanetetraacetic acid, amino acid or polyamino acid, oligo- or poly-ethylene glycol, amine, quaternary ammonium ion, sugar, glucosamine, galactosamine, mannosamine, polyethylene glycol (PEG) and its derivatives such as alkane Oxyethylene glycol (e.g., methoxypolyethylene glycol, ethoxypolyethylene glycol, etc.), branched polypropylene glycol, polypropylene glycol, polylysine and methoxypolyethylene glycol graft copolymers, peptides, lipids, fatty acids, palmitate, phospholipids, phospholipid-PEG conjugates, carbohydrates (e.g., dextran, aminodextran, carboxymethyldextran), iron oxide nanoparticles, naphthylalanine, phenylalanine, 3,3-diphenylpropylamine, taurine, phosphonates, phosphates, carboxylates and polycarboxylates. In other embodiments, the chemical modifier M reduces the nonspecific cell membrane permeability of the agent. In other embodiments, the chemical modifier M reduces the nonspecific tissue accumulation of the agent when administered to a living animal.
[0037] In certain embodiments, the linker or connector component (L) comprises a divalent radical selected from the group consisting of glycine, alanine, β-alanine, -NH-(CH 2 ) n-C(=O)-, where n=1-8, 4-aminomethylbenzoic acid, cysteine, glutamic acid, amino-polyethylene glycol-carboxylic acid, amino-polyethylene glycol amine, ethylenediamine, propylenediamine, spermidine, spermine, hexamethylenediamine, and diamine-amino acids such as homolysine, lysine, ornithine, diaminobutyric acid and diaminopropionic acid, succinic acid, glutaric acid, suberic acid, adipic acid, amides, triazoles, ureas or thioureas.
[0038] Other exemplary bacteria targeting agents include compounds encompassed by Formulas V, VI, and VII as described in the detailed description.
[0039] Another aspect of the invention provides a pharmaceutical composition suitable for administration to a subject, comprising a compound described herein (eg, a bacteria imaging agent) and a pharmaceutically acceptable excipient.
[0040] Another aspect of the invention provides an in vivo imaging method comprising: (a) administering an agent described herein (e.g., a bacterial imaging agent) to a subject; (b) allowing the agent to distribute in the subject; and (c) detecting a signal emitted by the agent.
[0041] Another aspect of the present invention provides an in vivo optical imaging method, comprising: (a) administering an agent described herein (e.g., a bacterial imaging agent) to a subject, wherein the agent comprises a fluorescent dye; (b) distributing the agent in the subject; (c) exposing the subject to light of a wavelength that can be absorbed by the fluorescent dye; and (d) detecting a signal emitted by the agent.
[0042] Another aspect of the present invention provides an in vivo imaging method, wherein the signal emitted by the agent is used to construct an image. In certain embodiments, the image is a tomographic image. In certain embodiments, the present invention provides a method for in vivo optical imaging, wherein steps (a)-(c) are repeated at predetermined time intervals, thereby allowing the emission signal of the agent (e.g., bacterial imaging agent) to be evaluated in the subject over time. In certain embodiments, the present invention provides a method for in vivo optical imaging, wherein steps (a)-(d) are repeated at predetermined time intervals, thereby allowing the emission signal of the agent (e.g., bacterial imaging agent) to be evaluated in the subject over time. In certain embodiments, the present invention provides a method for in vivo imaging, wherein the subject is an animal or a human. In certain embodiments, the present invention provides a method for in vivo imaging, wherein in step (a), two or more imaging probes whose signal properties can be distinguished from each other are administered to the subject, wherein at least one of the imaging probes is an agent described herein (e.g., bacterial imaging agent). In certain embodiments, the present invention provides a method for in vivo optical imaging, wherein the irradiation and detection steps are performed using an endoscope, a catheter, a tomography system, a handheld optical imaging system, or an intraoperative microscope. In certain embodiments, the present invention provides an in vivo imaging method, wherein the presence, absence or level of the emission signal is indicative of a disease state. In certain embodiments, the present invention provides an in vivo imaging method, wherein the method is used to detect and / or monitor a disease. In certain embodiments, the disease is selected from bone disease, cancer, cardiovascular disease, environmental disease, skin disease, immune disease, genetic disease, infectious disease, inflammatory disease, metabolic disease, ophthalmic disease and respiratory disease.
[0043] Another aspect of the present invention provides an in vivo imaging method, wherein in step (a), cells labeled with an agent described herein (e.g., a bacterial imaging agent) are administered to the subject. In other embodiments, the signal emitted by the agent (e.g., a bacterial imaging agent) is used to monitor the transport and positioning of the cells.
[0044] Another aspect of the invention provides a method for imaging a bacterial infection in a subject, the method comprising: administering an agent to the subject; and (b) detecting the presence of the agent, thereby generating an image representing the bacterial infection. In certain embodiments, the invention provides a method for treating a disease in a subject, the method comprising administering an agent systemically or locally to the subject, wherein the agent comprises a radioactive marker that localizes in the disease area and emits an effective dose of radiation.
[0045] Another aspect of the present invention provides an in vitro imaging method, the method comprising: (a) contacting a sample with a reagent; (b) allowing the reagent to bind to a biological target; (c) optionally removing unbound reagent; and (d) detecting a signal emitted from the reagent to thereby determine whether the reagent has been activated or bound by the biological target. In other embodiments, the sample is a biological sample.
[0046] The compounds described herein bind effectively to anionic surfaces, particularly bacterial cell membranes, and are effective for in vitro and in vivo fluorescence imaging of bacteria, and are therefore useful for both therapeutic and diagnostic applications.
[0047] Another aspect of the present invention provides a method for in vitro and in vivo imaging using the fluorescent bacterial imaging agent. For optical in vivo imaging, the method includes (a) administering the bacterial targeting agent of the present invention to a subject; (b) distributing the bacterial targeting agent in the subject; (c) exposing the subject to light of a wavelength that can be absorbed by the fluorophore of the bacterial targeting agent; and (d) detecting the light signal emitted by the bacterial targeting agent. The signal emitted by the agent can be used to construct an image. In some embodiments, some of the images are tomographic images. In addition, it should be understood that the above steps can be repeated at predetermined time intervals, thereby allowing the subject to be evaluated for changes over time.
[0048] The bacteria targeting agent can be formulated into a pharmaceutical composition suitable for administration to a subject, such as an animal and / or a human subject. The pharmaceutical composition can include one or more bacteria targeting agents and one or more stabilizers in a physiologically acceptable carrier.
[0049] The subject may be a vertebrate, such as a mammal, such as a human being. The subject may also be a non-vertebrate used for laboratory research (such as Caenorhabditis elegans, Drosophila or other model organisms for research, etc.).
[0050] The bacteria targeting agent can include, for example, 1 to 5 bacteria targeting binding components (e.g., 2 to 5, 3 to 5, or 4 to 5 bacteria targeting binding components), each of which is chemically linked to the imaging reporter. The agent can include multiple bacteria targeting components, each of which is chemically linked to the imaging reporter.
[0051] The imaging reporter can be, for example, selected from a fluorophore reporter, a fluorescent dye reporter, an optical reporter, a magnetic reporter, a radiolabel, an X-ray reporter, an ultrasound imaging reporter, a nanoparticle-based reporter, or a combination thereof. The bacterial imaging agent can also include a biological modifier chemically linked to the bacterial targeting component or the imaging reporter.
[0052] In addition, another aspect of the present invention provides a method for in vitro and in vivo imaging using the bacterial targeting agent. For optical in vivo imaging, an exemplary method includes (a) administering one or more of the above-mentioned bacterial targeting agents of the technology described herein to a subject, wherein the agent comprises one or more fluorescent dyes; (b) distributing the agent in the subject; (c) exposing the subject to light of a wavelength that can be absorbed by the at least one fluorescent dye; and (d) detecting the signal emitted by the bacterial targeting agent. The signal emitted by the agent can be used to construct an image, such as a tomographic image. In addition, it should be understood that the above steps can be repeated at predetermined time intervals, thereby allowing the subject to be evaluated for changes over time.
[0053] The bacterial targeting agent can be used to measure the number of bacterial cells (bacterial infection) or other physiological processes such as cell death in a subject. An exemplary method includes (a) administering one or more of the above-mentioned bacterial targeting agents to a subject; (b) detecting the presence of the agent, thereby generating an image representing the site of bacterial infection in the subject.
[0054] In each of the above methods, the subject can be a vertebrate, such as a mammal, such as a human. The subject can also be a non-vertebrate used for laboratory research (such as Caenorhabditis elegans (C.elegans), Drosophila or other research model organisms, etc.).
[0055] In addition, the bacterial targeting agent can be incorporated into a kit, such as a kit with optional instructions for using the bacterial targeting agent in an in vivo or in vitro imaging method. The kit can optionally include components that facilitate the use of the bacterial targeting agent, such as buffers and other formulations. Alternatively, the kit can include a medical device that facilitates the administration and / or detection of the bacterial targeting agent to a subject.
[0056] Other features and advantages of the invention will be apparent from the following drawings, detailed description, and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 shows in vitro binding studies between a bacteria targeting agent (Compound A7) and bacterial species Escherichia coli and Staphylococcus epidermidis. Figure 1A is a series of scatter plots comparing bacteria unbound and bound to a bacterial targeting agent using flow cytometry. Figure 1B yes Figure 1A Shown is a histogram of fluorescence between bacteria not bound or bound by a bacterial targeting agent obtained by flow cytometry.
[0058] FIG. 2 shows tomographic images and total fluorescence of the site of Staphylococcus epidermidis bacterial infection detected in mice using a bacteria targeting agent (Compound A7). Figure 2A Tomographic images of mice at 1, 2, and 3 hours post infection are shown. Figure 2B are bar graphs comparing fluorescence between infected and control (uninfected) legs of mice at 1, 2, and 3 hours post infection.
[0059] Figure 3 Shown are tomographic images of Escherichia coli (E. coli) bacterial infection sites detected in mice using a bacteria targeting agent (Compound A7). Figure 3 Tomographic images of mice at 1, 2, and 3 hours post infection are shown. Detailed Description
[0060] The present invention provides compositions and methods for detecting bacteria in a subject. The technology described herein is based in part on the discovery that fluorescent bacteria targeting agents can be produced that are stable, biocompatible, exhibit low in vitro nonspecific cellular uptake and low in vivo nonspecific tissue uptake, and can be used in various in vitro and in vivo assays and imaging applications and various therapeutic applications. Various aspects of the bacteria targeting agents and their uses are described in the following sections. The aspects of the invention described in a particular section are not limited to any particular section. In addition, if a variable is not accompanied by a definition, the previous definition of the variable shall prevail.
[0061] I. Bacteria Targeting Agents
[0062] Another aspect of the present invention provides a bacterial targeting agent. Generally speaking, the bacterial targeting agent comprises: (i) a bacterial targeting component and (ii) an imaging reporter, wherein the imaging reporter can be a fluorophore. The bacterial targeting component can be connected to the imaging reporter via a linker, as represented by the following formula:
[0063]
[0064] By selecting specific types of imaging reporter components, linkers, and bacterial targeting agents, the properties of the bacterial targeting agent can be adjusted. In addition, by attaching one or more chemical modification groups (M), the properties of the bacterial targeting agent can be adjusted. The bacterial targeting components, linkers, imaging reporters, and chemically modified components are described in more detail in the following subsections.
[0065] An "imaging reporter" or "IR" may be any suitable chemical or substance used to provide contrast or signal in imaging and detectable by an imaging technique. In certain embodiments, the imaging reporter comprises one or more fluorophores, photoluminescent nanoparticles, radioisotopes, superparamagnetic agents, X-ray contrast agents, and ultrasound agents. It should be understood that IR may also comprise therapeutic reporters, such as porphyrins used in photodynamic therapy and radionuclides used in radiation therapy.
[0066] The term "chemical modification group" or "M" is understood to refer to any moiety that can be used to alter the physical, chemical or biological properties of a bacterial targeting agent, such as, but not limited to, making it more water soluble or more dispersible in an administration medium compared to a bacterial targeting agent not modified with M, improving binding specificity, increasing or decreasing the net charge of the molecule, decreasing immunogenicity or toxicity, or altering cellular uptake, pharmacokinetics or biodistribution.
[0067] Additional information related to bacterial targeting agents can be found, for example, in U.S. Patent No. 7,833,737, and International Application Publication Nos. WO2006 / 137092, WO2008 / 124703, WO2010 / 147666, and WO2010 / 065906, all of which are incorporated herein by reference in their entireties.
[0068] A. Bacterial Targeting Component
[0069] Bacteria targeting moieties are generally organic functional groups containing at least one ammonium group. Exemplary bacteria modifying moieties include: (i) substituted heterocyclic groups containing one tetravalent ring nitrogen atom, (ii) substituted heterocyclic groups containing two tetravalent ring nitrogen atoms, and (iii) ammonium substituted heteroalkyl groups. In certain embodiments, the bacteria targeting moiety is one of the following:
[0070]
[0071] Where R 1 is an alkyl group, R 2 is alkyl or -alkylene-C(O)N(R 3 ) 2 , where R 3 represents independently at each occurrence hydrogen, alkyl, or two R 3 Together with the nitrogen to which they are attached they form a heterocyclic ring.
[0072] In certain other embodiments, the bacterial targeting moiety is one of the following: (a) a substituted heterocyclic group containing one tetravalent ring nitrogen atom, such as alkyl-substituted piperazine or alkyl-substituted DABCO, (b) a substituted heterocyclic group containing two tetravalent ring nitrogen atoms, such as alkyl-substituted piperazine or alkyl-substituted DABCO, or (c) wherein R' independently represents an alkyl group or hydrogen at each occurrence; n is 1, 2, 3 or 4; and A independently represents an anion at each occurrence, such as alkyl-CO 2 - .
[0073] Other exemplary bacterial targeting moieties contemplated for use in the present invention include those described in, for example, U.S. Patent No. 7,833,737, and International Patent Application Publication Nos. WO2006 / 137092, WO2008 / 124703, WO2010 / 147666, and WO2010 / 065906, all of which are incorporated herein by reference in their entireties.
[0074] B. Imaging Reporter
[0075] Various imaging reporters, such as fluorescent and non-fluorescent reporters, are contemplated to be suitable for use in the present invention. Exemplary imaging reporters are described below, including imaging reporters having fluorescent components, magnetic components, or radioactive isotopes. The imaging reporters can be substituted with multiple chemically modified components.
[0076] (a) Fluorescent reporter
[0077] In certain embodiments, the imaging reporter is a fluorophore molecule. "Fluorophore" includes, but is not limited to, fluorescent dyes, fluorescent dye quencher molecules, any organic or inorganic dyes, metal chelates, or any fluorescent enzyme substrate, including enzyme substrates activatable by proteases.
[0078] In some embodiments, the bacteria targeting agent comprises a fluorophore. In some embodiments, the fluorophore is a far-red and near-infrared fluorescent dye (NIRF) having maximum absorption and emission between about 600 to about 1200 nm, more preferably between about 600 nm to about 900 nm. It should be appreciated that the use of fluorescent dyes with excitation and emission wavelengths in other spectra may also be used in the compositions and methods of the present invention. Exemplary fluorescent dyes include, but are not limited to, carbocyanine fluorescent dyes and indigo fluorescent dyes.
[0079] The near-infrared fluorescent dye preferably has a relative humidity of at least 50,000 M per fluorescent dye molecule in an aqueous medium. -1 cm -1The near-infrared fluorescent dyes preferably also have (1) high quantum yields (i.e., quantum yields greater than 5% in aqueous media), (2) narrow excitation / emission spectra, spectrally separated absorption and emission spectra (i.e., the maximum excitation and emission values are at least 15 nm apart), (3) high chemical and photostability, (4) non-toxicity, (5) good biocompatibility, biodegradability and excretability, and (6) commercial feasibility and large-scale production in large quantities (i.e., gram and kilogram quantities) required for in vivo and human use.
[0080] Certain carbocyanine or polymethine fluorescent dyes can be used to produce the bacterial targeting agents of the present invention, and include, for example, those described in U.S. Patent No 6,747,159, U.S. Patent No 6,448,008, U.S. Patent No 6,136,612, U.S. Patent No 4,981,977, 5,268,486, U.S. Patent No 5,569,587, U.S. Patent No 5,569,766, U.S. Patent No 5,486,616, U.S. Patent No 5,627,027, U.S. Patent No 5,808,044, U.S. Patent No 5,877,310, U.S. Patent No 6,002,003, U.S. Patent No 6,004,536, U.S. Patent No 6,008,373, U.S. Patent No 6,043,025, U.S. Patent No 6,127,134, U.S. Patent No 6,130,094, U.S. Patent No 6,133,445 and described in WO 97 / 40104, WO 99 / 51702, WO 01 / 21624 and EP 1 065 250 A1 and Tetrahedron Letters 41, 9185-88 (2000).
[0081] Various fluorescent dyes are commercially available and can be used to construct the bacterial targeting agents of the present invention. Exemplary fluorescent dyes include, for example, Cy5.5, Cy5, and Cy7 (GE Healthcare); AlexaFluor660, AlexaFluor680, AlexaFluor750, and AlexaFluor790 (Invitrogen); VivoTag680, VivoTag-S680, and VivoTag-S750 (VisEnMedical); Dy677, Dy682, Dy752, and Dy780 (Dyomics); DyLight547, DyLight647 (Pierce); HiLyte Fluor 647, HiLyte Fluor 680, and HiLyte Fluor 750 (AnaSpec); IRDye800CW, IRDye 800RS, and IRDye 700DX (Li-Cor); and ADS780WS, ADS830WS, and ADS832WS (American Dye Source) and Kodak X-SIGHT 650, Kodak X-SIGHT 691, Kodak X-SIGHT 751 (Carestream Health).
[0082] Table 1 lists a number of exemplary commercially available fluorescent dyes and their spectral properties that can be used in the practice of the present invention.
[0083] Table 1
[0084] Fluorescent dyes <![CDATA[ε max M -1 cm -1 ]]> Maximum absorption wavelength (nm) Cy5 250,000 649 Cy5.5 250,000 675 Cy7 250,000 743 AlexaFlour660 132,000 663 AlexaFlour680 184,000 679 AlexaFlour750 280,000 749 VivoTag680(VT680) 100,000 670 VivoTag-S680 220,000 674 VivoTag-S750 100,000 750 Dy677 180,000 673 Dy682 140,000 690 Dy752 270,000 748 Dy780 170,000 782 DyLight547 150,000 557 DyLight647 250,000 653 IRDye800CW 240,000 774 IRDye800RS 200,000 767 IRDye700DX 165,000 689 ADS780WS 170,000 782 ADS830WS 240,000 819 ADS832WS 190,000 824
[0085] In certain embodiments, the fluorophore is substituted with a plurality of chemical modification groups. In one embodiment, the fluorophore is represented by formula A or a salt thereof:
[0086]
[0087] in:
[0088] W represents a benzo-fused, naphtho-fused or pyrido-fused ring;
[0089] X is independently selected at each occurrence from C(CH 2 Y 1 )(CH 2 Y 2 ), O, S and Se;
[0090] Y 1 and Y 2 is independently selected from H and C optionally substituted by L-M 1 -C 20The group consisting of aliphatic groups;
[0091] L, at each occurrence, independently represents a linker or a linker component;
[0092] M, at each occurrence, independently represents a chemically modified moiety; and
[0093] Represents the point where the fluorescent dye is bound to the linker or imaging reporter.
[0094] In one embodiment, the fluorescent dye is represented by Formula B or a salt thereof:
[0095]
[0096] in:
[0097] X is independently selected from C(CH 2 Y 1 )(CH 2 Y 2 ), O, S and Se;
[0098] Y 1 and Y 2 are independently selected from H, C 1 -C 20 Aliphatic groups and -OR*, N(R * ) 2 or -SR* substituted C 1 -C 20 The group consisting of aliphatic groups;
[0099] W represents a benzo-fused, naphtho-fused or pyrido-fused ring;
[0100] R* is an alkyl group;
[0101] R 1 Is selected from (CH 2 ) x CH 3 , (CH 2 ) n SO 3 - and (CH 2 ) n SO 3 H, wherein x is an integer selected from 0 to 6, and n is an integer selected from 2 to 6;
[0102] R 4 Is selected from (CH 2 ) x CH 3 , (CH 2 ) nSO 3 - and (CH 2 ) n SO 3 H, wherein x is an integer selected from 0 to 6, and n is an integer selected from 2 to 6;
[0103] R 2 and R 3 is independently selected from H, carboxylate, carboxylic acid, carboxylate ester, amine, amide, sulfonamide, hydroxyl, alkoxy, sulfonate
[0104] an acid moiety and a sulfonate moiety; and
[0105] Q is selected from the group consisting of a carboxyl-substituted heteroaryl ring and a carbonyl-substituted 6-membered heteroaryl ring; or Q is selected from the group consisting of (i) a carboxyl-functionalized heterocycle, (ii) a carboxyl-functionalized nitrogen-containing heterocycle, (iii) a carboxyl-functionalized nitrogen-containing 6-membered heterocycle such as pyridine, pyrimidone, pyrazine and pyridazine, (iv) a carboxyl-functionalized nitrogen-containing 6-membered heterocycle such as pyridine, (v) a carbonyl-functionalized nitrogen-containing 6-membered heterocycle such as pyridine, and (vi) isonicotinic acid, nicotinic acid and picolinic acid, and a group selected from one of the following:
[0106]
[0107] Here, the carboxyl group is also in the form of an ester, an active ester or a carbonyl halide capable of reacting with a nucleophile, and may be, for example, -C(O)-O-benzotriazolyl, -C(O)-O-(N-hydroxysuccinimide), -C(O)-O-tetrafluorophenyl, -C(O)-O-pentafluorophenyl, -C(O)-O-imidazole and -C(O)-O-p-nitrophenyl.
[0108] The free base of the fluorescent dye represented by Formula B can be bonded to a linker or directly bonded to an imaging reporter. In certain embodiments, the free base of Formula B is one in which one or more variable R 2 The group is -S(O 2 )N(alkyl)- free radical.
[0109] In another embodiment, the fluorescent dye is represented by Formula C or a salt thereof:
[0110]
[0111] in:
[0112] X 1 and X 2 are independently selected from C(CH 2 K 1 )(CH 2 K2 ), O, S and Se;
[0113] K 1 and K 2 independently H or C 1 -C 20 Aliphatic group; or K 1 With K 2 together are part of a substituted or unsubstituted carbocyclic or heterocyclic ring;
[0114] Y 1 and Y 2 are each independently a benzo-fused ring, a naphthalene-fused ring, or a pyrido-fused ring;
[0115] n 1 is 1, 2, or 3;
[0116] R 2 , R 11 and R 12 are independently H, halogen, alkyl, alkoxy, aryloxy, aryl, sulfonate, iminium ion, or any two adjacent R 12 and R 11 The substituents, when combined together, form an optionally C 1 -C 6 4-, 5- or 6-membered carbocyclic rings substituted once or multiple times by alkyl or halogen;
[0117] R 1 and R 13 Yes (CH 2 ) x CH 3 , wherein x is an integer selected from 0 to 6; or R 1 and R 13 Independently (CH 2 ) n SO 3 - or (CH 2 ) n SO 3 H, wherein n is an integer selected from 2 to 6;
[0118] R 3 , R 4 and R 5 are independently selected from the group consisting of H, carboxylate, carboxylic acid, carboxy ester, amine, amide, sulfonamide, hydroxyl, alkoxy, sulfonic acid moiety and sulfonate moiety;
[0119] R 6 is unsubstituted C 1 -C 20 an aliphatic group, an unsubstituted aryl group, or an unsubstituted alkylaryl group;
[0120] R 7 is H, unsubstituted C 1 -C 20 an aliphatic group, an unsubstituted aryl group or an unsubstituted alkylaryl group, wherein R 7 is optionally substituted with halogen; or
[0121] R 6 and R 7 taken together to form a 4-, 5-, 6- or 7-membered heterocyclic ring optionally substituted by halogen;
[0122] W does not exist, or is selected from -SO 2 NR 6 -Q-CHR 7 -, -O-, -C(O)O- and -C(O)N(H)-;
[0123] h = 0-70; k = 0 or 1; d = 0-12; m = 0-12; p = 0-12; and
[0124] Represents the point where the fluorescent dye is bound to the linker or imaging reporter.
[0125] Some exemplary chemically modified fluorophores that can be used in the synthesis of the bacterial targeting agents of the present invention include, for example, those listed in Table 2.
[0126] Table 2
[0127]
[0128]
[0129]
[0130]
[0131] In certain embodiments, one or more fluorescent dye molecules can be chemically linked to a bacterial targeting moiety to produce a fluorescent bacterial targeting agent.
[0132] In the case where the imaging reporter is a fluorescent dye molecule, the extinction coefficient of the bacterial targeting agent can be calculated as the ratio of the absorbance value of the dye at its maximum absorption wavelength (e.g., ~670 nm for VivoTag 680) to the concentration of the particle in a 1 cm pathlength cuvette using the formula ε = A / cl, where A is the absorbance value, c is the molar concentration, and l is the pathlength in cm.
[0133] It should be understood that the bacteria targeting agent can be attached to nanoparticles (e.g., silicon-containing nanoparticles) to produce fluorescent or luminescent nanoparticles. Aggregates of crystalline silicon (as polycrystals or single crystals of silicon), porous silicon or amorphous silicon, or a combination of these forms, can form nanoparticles. Preferred fluorescent silicon nanoparticles have a diameter between about 0.5 nm and about 25 nm, more preferably between about 2 nm and about 10 nm. The size of the nanoparticles can be determined by laser scattering or by atomic force microscopy or other suitable techniques.
[0134] Fluorescent silicon nanoparticles may have excitation and emission spectra between 200 and 2000 nm, however, preferred fluorescent silicon nanoparticles have maximum excitation and emission values between about 400 nm and about 1200 nm (preferably 500 nm-900 nm, such as 500 nm-600 nm, 600 nm-700 nm, 700 nm-800 nm or 800 nm-900 nm). Preferred fluorescent silicon nanoparticles also have at least 50,000 nm in aqueous media. -1 cm -1 Although fluorescent silicon nanoparticles having maximum excitation and emission values between 400nm and 1200nm are preferred, it should be recognized that the use of fluorescent silicon nanoparticles with excitation and emission wavelengths in other spectra can also be used in the compositions and methods of the present invention. For example, in some embodiments, the particles may have an excitation value of approximately about 300-350nm and an emission value of approximately about 400-450nm.
[0135] Fluorescent silicon nanoparticles may also have the following properties for use in vivo and in the human body: (1) high quantum yield (i.e., greater than 5% quantum yield in aqueous media), (2) narrow emission spectra (i.e., less than 75 nm, more preferably less than 50 nm), (3) spectrally separated absorption and emission spectra (i.e., more than 20 nm apart, more preferably more than 50 nm apart), (4) high chemical and photostability (i.e., retain luminescent properties after exposure to light), (5) be biocompatible (see below) or be made more biocompatible, (6) be non-toxic or minimally toxic to cells or subjects at doses used in imaging protocols (e.g., as determined by LD 50 or irritation test or other similar methods known in the art), and / or (6) commercial feasibility and large-scale production in large quantities (i.e., gram and kilogram quantities).
[0136] Other exemplary fluorophores include metal oxide nanoparticles that produce fluorescence and can be used in a variety of in vitro and in vivo applications. In one embodiment, the bacterial targeting moiety is conjugated to a fluorescent metal oxide nanoparticle having one or more of the following characteristics: (1) suitable for binding multiple fluorescent dyes, thereby obtaining a large extinction coefficient (greater than 1,000,000 M - 1 cm -1 ), (2) a non-crosslinked polymer coating suitable for binding about 10 to about 300 fluorescent dyes per particle, (3) a polymer coating suitable for binding multiple fluorescent dyes in a manner that does not significantly compromise the quantum yield of the fluorescent dye (e.g., when tested under the same conditions, the nanoparticle retains at least 50% of the fluorescent signal generated by substantially the same number of free fluorescent dyes), and (4) a polymer coating suitable for efficient chemical attachment of biomolecules while retaining their biological properties to produce molecular imaging agents. Both before and after chemical attachment of the fluorescent dye and the bacterial targeting agent, the fluorescent metal oxide nanoparticles are highly stable molecular imaging agents in vitro, but remain unstable and / or degradable in vivo.
[0137] Bacteria targeting components can be attached to fluorescent quantum dots such as amine T2 MP EviTags (Evident Technologies) or Qdot nanocrystals (Invitrogen). In general, fluorescent quantum dots are nanocrystals containing atoms of several semiconductor materials, including but not limited to those containing cadmium and selenium, sulfides or tellurium, zinc sulfide, indium-antimony, lead selenide, gallium arsenide and silicon dioxide or organically modified silicates, which have been coated with zinc sulfide to improve the properties of these fluorescent agents.
[0138] In addition, the bacterial targeting moiety can be conjugated to molecules capable of inducing photodynamic therapy. These molecules include, but are not limited to, Photofrin, Lutrin, Antrin, aminolevulinic acid, hypericin, benzoporphyrin derivatives, and selective porphyrins.
[0139] (b) Non-fluorescent reporters
[0140] As used herein, the term "non-fluorescent reporter" refers to a chemical moiety that does not fluoresce but can be used to provide contrast or signal in imaging and can be detected by non-fluorescent imaging techniques. In certain embodiments, other non-fluorescent reporters can be chemically linked to the imaging agent or can be administered to the subject simultaneously or sequentially with the imaging agent of the present invention. Such reporters can include photoluminescent nanoparticles, radioisotopes, superparamagnetic agents, X-ray contrast agents, and ultrasound agents. Reporters can also include therapeutic reporters used in photodynamic therapy such as porphyrins, Aminolevulinic acid, hypericin, benzoporphyrin derivatives, and radionuclides used in radiotherapy.
[0141] (i) Radioactive reporter
[0142] The agent may include one or more radioactive labels. Radioactive isotope forms of metals such as copper, gallium, indium, technetium, yttrium, and lutetium can be chemically linked to the metal imaging agent and can be used for nuclear imaging or therapeutic applications. Exemplary radioactive labels include, but are not limited to 99m Tc, 111 In, 64 Cu, 67 Ga, 186 Re, 188 Re, 153 Sm, 177 Lu and 67 Cu.
[0143] Other exemplary markers include, for example 123 I. 124 I. 125 I. 11 C. 13 N. 15 O and 18 F. Other exemplary markers may be therapeutic radiopharmaceuticals, including, for example 186 Re, 188 Re, 153 Sm, 166 Ho, 177 Lu, 149 Pm, 90 Y. 212 Bi, 103 Pd, 109 Pd, 159 Gd, 140 La, 198 Au, 199 Au, 169 Yb, 175 Yb, 165 Dy, 166 Dy, 67 Cu, 105 Rh, 111 Ag and 192 Ir.
[0144] Chelating agents or binding moieties for use in diagnostic and therapeutic radiopharmaceuticals are also contemplated and can be chemically linked to imaging agents. Exemplary chelating agents can be selected to bind to radioisotopes with imageable gamma or positron emitting properties, such as 99m Tc, 111 In, 64 Cu and67 Ga forms a stable complex. Exemplary chelating agents include diamine dithiols, monoamine-monoamide dithiols, triamide-monothiols, monoamine-diamide-monothiols, diamine dioximes, and hydrazines. Chelating agents are generally tetracoordinated, have donor atoms selected from nitrogen, oxygen and sulfur, and can include, for example, cyclic and non-cyclic polyaminocarboxylates such as diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), (DO3A), 2-benzyl-DOTA, α-(2-phenylethyl)1,4,7,10-tetraazacyclododecane-1-acetyl-4,7,10-tri(methylacetyl) acid, 2-benzyl-cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl-6-methyl-DTPA and 6,6"-bis[N,N,N",N"-tetra(carboxymethyl)aminomethyl)-4'-(3-amino-4-methoxyphenyl)-2,2':6',2"-terpyridine.
[0145] (ii) Magnetic reporter
[0146] Other exemplary reporters may include chelators for magnetic resonance agents. Such chelators may include, for example, polyamine-polycarboxylate chelators or iminoacetic acid chelators that may be chemically linked to the agent.
[0147] Chelating agents for magnetic resonance imaging agents can be selected to form stable complexes with paramagnetic metal ions such as Gd(III), Dy(III), Fe(III) and Mn(II), and the chelating agents are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, DO3A, 2-benzyl-DOTA, α-(2-phenylethyl)1,4,7,10-tetraazacyclododecane-1-acetyl-4,7,10-tri(methylacetyl) acid, 2-benzyl-cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl-6-methyl-DTPA and 6,6"-bis[N,N,N",N"-tetrakis(carboxymethyl)aminomethyl)-4'-(3-amino-4-methoxyphenyl)-2,2':6',2"-terpyridine.
[0148] In one embodiment, the bacterial targeting agent is conjugated to superparamagnetic metal oxide nanoparticles that are (a) non-fluorescent or (b) fluorescent and can be used in a variety of in vitro and in vivo applications. Fluorescent metal oxide nanoparticles that also have magnetic properties can be used in MRI, thus providing a multimodal imaging agent.
[0149] In certain embodiments, the imaging agent may include fluorescent and / or non-fluorescent superparamagnetic metal oxide nanoparticles having one or more of the following features: (1) a polymer coating suitable for binding multiple agents, (2) a non-crosslinked polymer coating suitable for binding about 10 to about 300 agents per particle, and (3) a polymer coating suitable for efficient chemical attachment of agents while retaining their biological properties to produce molecular imaging agents. The agent-modified metal oxide nanoparticles can be highly stable molecular imaging agents in vitro, both before and after chemical attachment of agents, but remain unstable and / or degradable in vivo.
[0150] The bacteria targeting agent conjugated metal oxide nanoparticles can be formulated into pharmaceutical compositions suitable for administration to a subject, such as an animal and / or a human subject.
[0151] (iii) Ultrasonic reporter
[0152] For ultrasound imaging, the imaging reporter may include gas-filled bubbles such as Levovist, Albunex or Echovist or particles or metal chelators, wherein the metal ions have an atomic number of 21-29, 42, 44 or 57-83. Examples of such compounds are described in Tyler et al., Ultrasonic Imaging, 3, pp. 323-29 (1981) and D.P. Swanson, "Enhancement Agents for Ultrasound: Fundamentals", Pharmaceuticals in Medical Imaging, pp. 682-87 (1990).
[0153] (iv) X-ray reporter
[0154] Exemplary reporters may include iodinated organic molecules or chelators of heavy metal ions having atomic numbers 57 to 83. Examples of such compounds are described in Radiocontrast Agents, edited by M. Sovak, Springer-Verlag, pp. 23-125 (1984) and in U.S. Pat. No. 4,647,447.
[0155] C. Connector
[0156] The linker or spacer component (L) can be used to chemically link one or more chemical modifiers (M) to the fluorophore, and / or to link the bacterial targeting component to Q, or if Q is absent, directly to the fluorophore of the reagent of the invention. Useful linker components include both natural and non-natural amino acids and nucleic acids, peptides such as glycine, β-alanine, γ-aminobutyric acid or aminocaproic acid, and synthetic linker molecules such as aminoethylmaleimide or aminomethylbenzoic acid, or polymers such as homo- or hetero-bifunctional polyethylene glycol (PEG). When the linker is a peptide, the peptide may optionally include a proteolytic cleavage site, which can be cleaved with various agents such as enzymes.
[0157] It should be understood that there is no particular structural, size or inclusion limitation for a given linker.The linker may include, for example, various functional groups such as maleimide, dithiopyridyl, thiol, azide, olefin or alkyne, which allow the molecular assembly to have a diverse structure.
[0158] The linker can be a homofunctional linker or a heterofunctional linker. For example, an amine (NH 2 ) functionalized components can react with bifunctional crosslinkers designed to react with amino groups. Particularly useful coupling reagents that can promote linker formation or promote covalent attachment between, for example, a fluorophore and an enzymatically cleavable oligopeptide can include N-hydroxysuccinimide (NHS) esters and / or maleimides. NHS esters can react with, for example, amine groups of a peptide or fluorophore. Maleimide can react with the sulfhydryl group of another molecule. Other particularly useful linker components are bifunctional crosslinkers such as N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), long chain SPDP, maleimidobenzoic acid-N-hydroxysuccinimide ester (MBS), succinimidyl trans-4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl iodoacetate (SIA).
[0159] In some embodiments, the linker, if present, can be a derivative of a diamine. A diamine component or derivative can be provided with a linker arm of different lengths and chemical properties for chemically linked molecules by optionally deriving with a carboxylic acid. Non-limiting examples of diamines include ethylenediamine (EDA), propylenediamine, spermidine, spermine, hexamethylenediamine, and diamine-amino acids such as homolysine, lysine, ornithine, diaminobutyric acid, and diaminopropionic acid. In other embodiments, the imaging agent component can be chemically linked to a dicarboxylic acid, such as succinic acid, glutaric acid, suberic acid, or adipic acid. In one embodiment, the linker is aminoethylmaleimide.
[0160] In certain embodiments, the linker can be branched, such as glutamic acid or 5-(aminomethyl)isophthalic acid, or a dendrimer, such as a lysine or glutamic acid dendrimer, with multiple M groups attached to a single site on the fluorophore.
[0161] In certain embodiments, L is a functionalized substituted or unsubstituted C 1 -C 18 In some embodiments, L is an alkyl, alkenyl, alkynyl, alkoxy or sulfanyl group. In other embodiments, L is a functionalized substituted or unsubstituted aromatic or heteroaromatic ring. In other embodiments, L is absent.
[0162] In certain embodiments, the linker can be formed from an azide moiety that can react with a substituted alkyne in an azide-acetylene dipole (Huisgen) [3+2] cycloaddition reaction. In certain embodiments, an azide or alkyne linker can link a polyethylene glycol (PEG) moiety to, for example, an enzymatically cleavable oligopeptide. Other contemplated linkers include propargylglycine, pentanoyl, pentynoic acid, propynoic acid, and / or propargylamine moieties.
[0163] In certain embodiments, the imaging reporter is chemically linked directly to the bacterial targeting moiety using a reactive NHS ester group on the IR that reacts with the amine group of the amino-functionalized bacterial targeting moiety. In certain other embodiments, the carboxylic acid group on the IR can be activated in situ by activators known in the art, such as 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), N,N'-dicyclohexylcarbodiimide (DCC), N,N'-disuccinimidyl carbonate (DSC). In other embodiments, the IR containing a sulfhydryl or thiol group can be chemically linked to the bacterial targeting moiety by a bifunctional crosslinker having a second component that is capable of reacting with a sulfhydryl (thiol) group. Such crosslinkers include, for example and as described above, SPDP, long chain SPDP, SIA, MBS, SMCC, and other crosslinkers known in the art.
[0164] Useful linker components include both natural and non-natural amino acids, oligopeptides such as linear or cyclic oligopeptides, and nucleic acids. The linker can be a peptide or a peptide component. The linker can optionally include a proteolytic or non-proteolytic cleavage site, such as an ester bond that can be cleaved at a desired site by a pH change.
[0165] As used herein, the term "amino acid" is understood to refer to an organic compound containing both a basic amino group and an acidic carboxyl group. Included in this term are natural amino acids (e.g., L-amino acids), modified and uncommon amino acids (e.g., D-amino acids), and amino acids known to exist in organisms in free or combined form but not usually present in proteins. Natural amino acids include, but are not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tyrosine, tyrosine, tryptophan, proline, and valine. Other amino acids include, but are not limited to, argininosuccinate, citrulline, cysteinesulfinic acid, 3,4-dihydroxyphenylalanine, homocysteine, homoserine, ornithine, carnitine, selenocysteine, selenomethionine, 3-monoiodotyrosine, 3,5-diiodotyrosine, 3,5,5'-triiodothyronine, and 3,3',5,5'-tetraiodothyronine.
[0166] Modified or unusual amino acids that can be used to practice the present invention include, but are not limited to, D-amino acids, hydroxylysine, deoxyalanine, pyrrolysine, 2-aminoisobutyric acid, γ-aminobutyric acid, 5-hydroxytryptophan, S-adenosylmethionine, S-adenosylhomocysteine, 4-hydroxyproline, N-Cbz-protected amino acids, 2,4-diaminobutyric acid, homoarginine, norleucine, N-methylaminobutyric acid, naphthylalanine, phenylglycine, β-phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3,4-deoxyproline, N,N-dimethylaminoglycine, N-methylaminoglycine, 4-aminopiperidine-4-carboxylic acid, 6-aminohexanoic acid, trans-4-(aminomethyl)-cyclohexanecarboxylic acid, 2-, 3-, and 4-(aminomethyl)-benzoic acid, 1-aminocyclopentanecarboxylic acid, 1-aminocyclopropanecarboxylic acid, and 2-benzyl-5-aminopentanoic acid.
[0167] As used herein, a "pseudo-peptide" or "peptide mimetic" is a compound that mimics the structure of an amino acid residue or peptide, for example by using a linking group other than an amide bond (pseudo-peptide bond) and / or by using non-amino acid substitutes and / or modified amino acid residues. A "pseudo-peptide residue" refers to the portion of a pseudo-peptide or peptidomimetic that is present in a peptide. The term "pseudo-peptide bond" includes peptide bond isosteres that can be used to replace or serve as a substitute for a normal amide bond. These substitutes or amide "equivalent" bonds are formed by a combination of atoms that simulate the steric requirements of an amide bond that is not normally present in a peptide or protein and that stabilize the molecule against enzymatic degradation. The following conventional three-letter amino acid abbreviations are used herein: Ala=alanine, Aca=aminocaproic acid, Ahx=6-aminocaproic acid, Arg=arginine, Asn=asparagine, Asp=aspartic acid, Cha=cyclohexylalanine, Cit=citrulline, Cys=cysteine, Dap=diaminopropionic acid, Gln=glutamine, Glu=glutamic acid, Gly=glycine, His=histidine, ile=isoleucine, Leu=leucine, Lys=lysine, Met=methionine, Nal=naphthylalanine, Nle=norleucine, Orn=ornithine, Phe=phenylalanine, Phg=phenylglycine, Pro=proline, Sar=sarcosine, Ser=serine, Thi=thienylalanine, Thr=threonine, Trp=tryptophan, Tyr=tyrosine, Val=valine. Use of the prefix D- indicates the D-isomer of the amino acid, for example D-lysine is indicated as D-Lys.
[0168] Peptides can be synthesized using solution phase chemistry or solid phase chemistry, or a combination of both (Albericio, Curr. Opinion. Cell Biol., 8, 211-221 (2004); M. Bodansky, Peptide Chemistry: A Practical Textbook, Springer-Verlag; NL Benoiton, Chemistry of Peptide Synthesis, 2005, CRC Press).
[0169] In order to prepare the reagent of the present invention, selective or orthogonal amine protecting groups may be required. When used in this article, the term "amine protecting group" refers to any group known in the field of organic synthesis for protecting amine groups. Such amine protecting groups are included in Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York (1981) and Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981) listed in those. Any amine protecting group known in the art can be used. Examples of amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl, phthaloyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, and 9-fluorenylmethoxycarbonyl (Fmoc); 3) aliphatic carbamate types such as tert-butoxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cycloalkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilanes such as trimethylsilane; and 7) thiol-containing types such as phenylthiocarbonyl and disulfosuccinyl. Also included in the term "amine protecting group" are acyl groups such as azidobenzoyl, p-benzoylbenzoyl, o-phenylmethylbenzoyl, p-acetylbenzoyl, dansyl, glycyl-p-benzoylbenzoyl, phenylbenzoyl, m-benzoylbenzoyl, benzoylbenzoyl.
[0170] In certain embodiments, the enzymatically cleavable oligopeptide may include oligo-L-arginine, oligo-L-lysine, oligo-L-aspartic acid, or oligo-L-glutamic acid.
[0171] The enzymatically cleavable oligopeptide can be cleaved by at least one enzyme selected from the group consisting of hydrolases, elastases, cathepsins, matrix metalloproteinases, peptidases, exopeptidases, endopeptidases, carboxypeptidases, glycosidases, lipases, nucleases, lyases, amylases, phospholipases, phosphatases, phosphodiesterases, sulfatases, serine proteases, subtilisins, chymotrypsin, trypsin, threonine proteases, cysteine proteases, calpains, papains, caspases, aspartic proteases, pepsins, chymosins, glutamic proteases, renin, reductases, and enzymes of parasites, viruses, and bacteria.
[0172] D. Chemical modifiers
[0173] Depending on the target application, the bacterial targeting agent may include one or more chemical modifiers (M) that can change the physical, chemical or biological properties of the bacterial targeting agent. Specifically, multiple M can be chemically linked to the fluorophore component of the agent. M can be the same at each occurrence, or it can be different. For example, M may make the bacterial targeting agent more useful for biological imaging, that is, for example, more soluble in water or more dispersible in a medium for administration, with increased binding specificity or less immunogenicity or less toxicity, or with reduced nonspecific binding, altered biodistribution and pharmacokinetics compared to an unsubstituted or less substituted fluorophore component.
[0174] For example, the combination of methoxypolyethylene glycol (mPEG) or polypeptides or multiple anionic M can play a role in adjusting the pharmacokinetics and blood clearance rate of bacterial targeting agents in vivo. Other M can be selected to accelerate the clearance of bacterial targeting agents from background tissues such as muscle or liver and / or from the blood, thereby reducing background interference and improving image quality. In addition, M can be used to promote specific excretion routes, such as through the kidneys instead of through the liver. M can also assist in formulating the probe in a pharmaceutical composition, or can be used to change or retain the signal reporting properties of the bacterial targeting agent. Specifically, the chemical connection of polyethylene glycol (PEG) or its derivatives to the bacterial targeting agent can cause a longer blood residence time (longer circulation) and reduce immunogenicity.
[0175] Exemplary modifying agents include polyethylene glycol (PEG) and its derivatives (e.g., alkoxy polyethylene glycol (e.g., methoxy polyethylene glycol, ethoxy polyethylene glycol, etc.)), branched polypropylene glycol, polypropylene glycol, graft copolymers of polylysine and methoxy polyethylene glycol, amino acids, peptides, lipids, fatty acids, palmitate, phospholipids, phospholipid-PEG conjugates, carbohydrates (e.g., dextran, aminodextran, carboxymethyldextran), iron oxide nanoparticles, sulfonates, polysulfonates, cysteic acid, naphthylalanine, phenylalanine and 3,3-diphenylpropylamine, taurine, phosphonates, phosphates, carboxylates and polycarboxylates.
[0176] In certain embodiments, the chemical modifier M is an anionic moiety selected from the group consisting of carboxylate, phosphonate, phosphate, iminodiacetate, cysteic acid, or taurine.
[0177] In certain embodiments, the chemical modifier M is a sulfonate or a polysulfonate.
[0178] In certain embodiments, the chemical modifier M is hydrogen, an alcohol, a sulfonamide, a sulfoxide, a sulfone, a ketone, an amino acid such as glutamic acid or taurine, a polyamino acid such as polycysteic acid, an oligo- or polyethylene glycol, an amine, a quaternary ammonium ion, or a sugar such as glucosamine, galactosamine, or mannosamine.
[0179] In certain embodiments, the chemical modifier M is a metal chelator such as ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) or tetraazacyclododecanetetraacetic acid (DOTA). In another aspect of the invention, one or more metal chelating M groups coordinate to a metal ion.
[0180] In certain embodiments, as discussed above, the biomodifier can be a PEG moiety having a molecular weight of, for example, about 0.1 kDa to about 50 kDa, about 5 kDa to about 35 kDa, or about 10 kDa to about 30 kDa. Alternatively, the PEG can be a dPEG functionalized with discrete molecular weights of, for example, about 1100 Daltons.
[0181] In certain embodiments, PEG is methoxy PEG. (5000) -Succinimidyl propionate (mPEG-SPA), methoxy PEG (5000) - Succinimidyl succinate (mPEG-SS). Such PEGS are commercially available from Nektar Therapeutics or SunBiowest or LaysanBio or NOF.
[0182] The PEG moiety can be conjugated to a reactive amine on the bacterial targeting agent via the carboxyl functional group. Alternatively, a thiol-reactive cross-linking agent can be used, which then reacts with the thiol group on the PEG to conjugate the PEG modifier to the bacterial targeting agent.
[0183] In one embodiment, the PEG may be branched or Y-shaped, as available from JenKem USA or NOF, or comb-shaped, or synthesized by coupling two or more PEGs to a small molecule such as glutamic acid.
[0184] In other embodiments, the biomodifier may be a polymer of the polyvinyl pyrrolidone (PVP) type. The biomodifier may be a functionalized polyvinyl pyrrolidone, such as a functionalized carboxyl or amine at one (or both) ends of the polymer (as available from Polymersource) or within the polymer chain.
[0185] Alternatively, the biomodifier may include poly (N-(2-hydroxypropyl)methacrylamide) (HPMA) or functionalized HPMA (amine, carboxyl, etc.), poly (N-isopropylacrylamide) or functionalized poly (N-isopropylacrylamide).
[0186] The biomodifier may include: straight chain or branched acyl groups, such as valeryl; acidic groups, such as succinyl; lower alkyl groups, such as methyl, ethyl, propyl, etc.; carboxyalkyl groups, such as carboxyethyl; halogenated alkyl groups, such as trifluoromethyl, etc.
[0187] In general, chemical attachment of M does not adversely affect the affinity and / or binding properties of the bacterial targeting agent.
[0188] E. First Class of Exemplary Bacteria Targeting Agents
[0189] The bacterial targeting moieties, imaging reporters, linkers, and optional chemically modified moieties described above can be combined in different arrangements to obtain a variety of bacterial targeting agents. Exemplary bacterial targeting agents are described below.
[0190] One aspect of the present invention provides a bacterial targeting agent comprising at least one bacterial targeting component chemically linked to a fluorophore, wherein a plurality of chemically modified components (M) are chemically linked to the fluorophore. Optionally, one or more linker (L) components may be used to chemically link the bacterial targeting component to the fluorophore or to chemically link M to the fluorophore.
[0191] In certain embodiments, the bacterial targeting agent will have an affinity for negatively charged cell surfaces, such as bacterial and apoptotic cell surfaces, including bacterial cell membranes. In other embodiments, the affinity for bacterial and apoptotic cell surfaces is higher than the affinity for healthy mammalian cell surfaces. As defined herein, a "bacterial targeting component" is a molecule that specifically binds to a negatively charged bacterial cell surface. The binding between the bacterial targeting component and the negatively charged cell surface can be covalent or non-covalent (e.g., electrostatic interactions, hydrophobic interactions, van der Waals interactions, hydrogen bonding, dipole interactions, etc.). The binding between the bacterial targeting component and the negatively charged cell surface is preferably non-covalent.
[0192] A "fluorophore" (F) can be any suitable chemical or substance that is used to provide a fluorescent signal or contrast in imaging and can be detected by an imaging technique. In certain embodiments, F comprises, for example, a cyanine dye, a carbocyanine dye, an indigo dye, or a polymethine fluorescent dye. In certain embodiments, F comprises a symmetrical cyanine dye. In other embodiments, F comprises an asymmetrical cyanine dye. In other embodiments, F can also be modified with a variety of chemical modifying groups to optimize the in vitro and in vivo properties of the agent and ultimately optimize the performance of the agent as a fluorescent imaging agent.
[0193] Bacteria targeting agents can have an affinity for the cell surface of bacteria, such as Gram-positive and Gram-negative bacteria. In one embodiment, the bacteria targeting agent also has an affinity for negatively charged apoptotic cells. In certain embodiments, the bacteria targeting agent binds to negatively charged cells that are upregulated during infection and apoptosis.
[0194] Another aspect of the present invention provides a bacteria targeting agent comprising:
[0195] (i) a bacterial targeting moiety comprising a positively charged moiety optionally substituted with an aliphatic, aromatic or heteroaromatic moiety; and
[0196] (ii) an imaging reporter, which is optionally chemically linked to the bacterial targeting moiety via a linker (L) moiety; and a fluorescent reporter, which is optionally chemically linked to the bacterial targeting moiety via a linker (L) moiety, wherein the fluorescent moiety carries a plurality of chemical modification groups.
[0197] The term "chemically linked" is understood to mean linked by attractive forces between atoms that are strong enough to allow the combined aggregate to function as a unit. This includes, but is not limited to, chemical bonds such as covalent bonds, non-covalent bonds such as ionic bonds, metallic bonds and bridge bonds, hydrophobic interactions, hydrogen bonds and van der Waals interactions.
[0198] Another aspect of the present invention provides a bacteria targeting agent comprising:
[0199] (i) a bacteria targeting moiety comprising a positively charged 1,4-diazabicyclo[2.2.2]octane (DABCO) moiety optionally substituted with an aliphatic, aromatic or heteroaromatic moiety; and
[0200] (ii) an imaging reporter, which is optionally chemically linked to the bacterial targeting moiety via a linker (L) moiety; and a fluorescent reporter, which is optionally chemically linked to the bacterial targeting moiety via a linker (L) moiety, wherein the fluorescent moiety carries a plurality of chemical modification groups.
[0201] F. Second Class of Exemplary Bacteria Targeting Agents
[0202] Another aspect of the present invention provides a bacterial targeting agent, which is a compound of formula (I) or a salt thereof:
[0203]
[0204] in:
[0205] Z is the bacteria targeting component, containing:
[0206] (a)
[0207] (b) aliphatic, aromatic or heteroaromatic moieties, each of which is optionally substituted; and
[0208] (c) if desired, one or more anions to obtain a charge-neutral compound;
[0209] L is independently a linker or a component of a connector at each occurrence;
[0210] Q is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 18 the group consisting of alkyl, alkenyl, alkynyl, alkoxy or sulfanyl, or is absent;
[0211] W represents a benzo-fused, naphtho-fused or pyrido-fused ring;
[0212] X is independently selected from C(CH 2 Y 1 )(CH 2 Y 2 ), O, S and Se;
[0213] Y 1 and Y 2 are independently selected from H and C optionally substituted by LM 1 -C 20 aliphatic groups; and
[0214] M at each occurrence is independently hydrogen or a chemically modified moiety.
[0215] In certain embodiments, Z is bonded to an aliphatic, aromatic, or heteroaromatic moiety, each of which is optionally substituted. and, if desired, one or more anions to obtain a charge-neutral compound. The aliphatic, aromatic or heteroaromatic component is bonded to In certain embodiments, L is a bond and M is hydrogen.
[0216] Another aspect of the present invention provides a bacterial targeting agent, which is a compound of formula (II) or a salt thereof:
[0217]
[0218] in:
[0219] Z represents the bacterial targeting component independently at each occurrence, including:
[0220] (a)
[0221] (b) aliphatic, aromatic or heteroaromatic moieties, each of which is optionally substituted; and
[0222] (c) if desired, one or more anions to obtain a charge-neutral compound;
[0223] L is independently a linker or a component of a connector at each occurrence;
[0224] Q is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 18 the group consisting of alkyl, alkenyl, alkynyl, alkoxy or sulfanyl, or is absent;
[0225] R at each occurrence independently represents hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 18 alkyl, alkenyl, alkynyl, alkoxy, or sulfanyl, each of which is optionally substituted with LM;
[0226] n is 1, 2, or 3;
[0227] W represents a benzo-fused, naphtho-fused or pyrido-fused ring;
[0228] X is independently selected from C(CH 2 Y 1 )(CH 2 Y 2 ), O, S and Se;
[0229] Y 1 and Y 2 are independently hydrogen or alkyl; and
[0230] M at each occurrence is independently hydrogen or a chemically modified moiety.
[0231] In certain embodiments, the chemical fragment "SO 2 NR-QLZ" is -S(O) 2 N(alkyl)-(C 1 -C 6 In certain embodiments, the compound contains one or more anions (e.g., alkyl-CO 2 - anion) to obtain a charge-neutral compound. In certain embodiments, R is hydrogen or methyl. In certain embodiments, X is C(CH 3 )2 In certain embodiments, Z is bonded to an aliphatic, aromatic, or heteroaromatic moiety, each of which is optionally substituted. and, if desired, one or more anions to obtain a charge-neutral compound. The aliphatic, aromatic or heteroaromatic component is bonded to In certain embodiments, L is a bond and M is hydrogen.
[0232] Another aspect of the present invention provides a bacterial targeting agent, which is a compound of formula (III) or a salt thereof:
[0233]
[0234] in:
[0235] Z is the bacteria targeting component, containing:
[0236] (a)
[0237] (b) aliphatic, aromatic or heteroaromatic moieties, each of which is optionally substituted; and
[0238] (c) if desired, one or more anions to obtain a charge-neutral compound;
[0239] L is independently a linker or a component of a connector at each occurrence;
[0240] Q is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 18 the group consisting of alkyl, alkenyl, alkynyl, alkoxy or sulfanyl, or is absent;
[0241] R at each occurrence independently represents hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 18 alkyl, alkenyl, alkynyl, alkoxy, or sulfanyl, each of which is optionally substituted with LM;
[0242] n is 1, 2, or 3;
[0243] W represents a benzo-fused, naphtho-fused or pyrido-fused ring;
[0244] X is independently selected at each occurrence from C(CH 2 Y 1 )(CH 2 Y 2 ), O, S and Se;
[0245] Y 1 and Y2 are independently hydrogen or alkyl; and
[0246] M is independently at each occurrence hydrogen or a chemically modified moiety.
[0247] In certain embodiments, the chemical fragment "SO2NR-QLZ" is -S(O)2N(alkyl)-(C1-C6 alkylene)-C(O)N(H)-alkylene-C(O)N(H)-arylene-alkylene-(substituted heterocyclyl containing two tetravalent ring nitrogen atoms). In certain embodiments, the compound contains one or more anions (e.g., alkyl-CO2-anions) when necessary to obtain a charge-neutral compound. In certain embodiments, Z is bonded to each optionally substituted aliphatic, aromatic, or heteroaromatic moiety. and, if desired, one or more anions to obtain a neutrally charged compound. The aliphatic, aromatic or heteroaromatic moiety is bonded to In certain embodiments, L is a bond and M is hydrogen.
[0248] In certain embodiments, R is hydrogen or methyl. In certain embodiments, X is C(CH 3 ) 2 .
[0249] In certain embodiments, the agent fluoresces in the far-red or near-infrared wavelengths.
[0250] Another aspect of the present invention provides a bacterial targeting agent, which is a compound of formula (IV) or a salt thereof:
[0251] F-(L) n -(Z) m
[0252] (IV)
[0253] in:
[0254] n=1-8
[0255] m = 1, 2, 3 or 4
[0256] F is a far-red or near-infrared fluorescent dye;
[0257] L is an optional linker; and
[0258] Z represents the bacterial targeting component independently at each occurrence, including:
[0259] (a)
[0260] (b) an aliphatic, aromatic, heteroaromatic or PEG moiety, each of which is optionally substituted; and
[0261] (c) if desired, one or more anions to obtain a charge-neutral compound.
[0262] In certain embodiments, the chemical modification moiety (M) is selected from hydrogen, alcohol, sulfonate, polysulfonate, cysteine, sulfonamide, sulfoxide, sulfone, carboxylate, ketone, phosphonate, phosphate, iminodiacetate, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, tetraazacyclododecanetetraacetic acid, amino acid or polyamino acid, oligo- or poly-ethylene glycol, amine, quaternary ammonium ion, sugar, glucosamine, galactosamine, mannosamine, polyethylene glycol (PEG) and its derivatives such as alkoxy Polyethylene glycol (e.g., methoxypolyethylene glycol, ethoxypolyethylene glycol, etc.), branched polypropylene glycol, polypropylene glycol, graft copolymers of polylysine and methoxypolyethylene glycol, peptides, lipids, fatty acids, palmitate, phospholipids, phospholipid-PEG conjugates, carbohydrates (e.g., dextran, aminodextran, carboxymethyldextran), iron oxide nanoparticles, naphthylalanine, phenylalanine, 3,3-diphenylpropylamine, taurine, phosphonates, phosphates, carboxylates, and polycarboxylates.
[0263] In other embodiments, the chemical modifier M reduces the non-specific cell membrane permeability of the agent. In other embodiments, the chemical modifier M reduces the non-specific tissue accumulation of the agent when administered to a living animal.
[0264] In certain embodiments, the linker or connector component (L) comprises a divalent radical selected from the group consisting of glycine, alanine, β-alanine, -NH-(CH 2 ) n -C(=O)-, where n=1-8, 4-aminomethylbenzoic acid, cysteine, glutamic acid, amino-polyethylene glycol-carboxylic acid, amino-polyethylene glycol amine, ethylenediamine, propylenediamine, spermidine, spermine, hexamethylenediamine, and diamine-amino acids such as homolysine, lysine, ornithine, diaminobutyric acid and diaminopropionic acid, succinic acid, glutaric acid, suberic acid, adipic acid, amides, triazoles, ureas or thioureas.
[0265] G. Third Class of Exemplary Bacteria Targeting Agents
[0266] One aspect of the present invention provides a compound represented by Formula V or a salt thereof:
[0267]
[0268] in:
[0269] X 1 and X 2Each independently represents hydrogen or one of the following groups, provided that X 1 and X 2 Not all hydrogen:
[0270] (a)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic radical containing one tetravalent ring nitrogen atom)-A
[0271] (b)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 ;or
[0272] (c)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(C 1 -C 6 Alkylene)
[0273] n is 1, 2, 3, or 4;
[0274] A is a monovalent anion or is absent;
[0275] Y is one of the following:
[0276] (a)ψ-alkylene-C(O)N(R 5 )-arylene-alkylene-; or
[0277] (b)ψ-heteroalkylene-C(O)N(R 5 )-alkylene-C(O)N(R 5 )-arylene-alkylene-;
[0278] ψ is the bond to the amide nitrogen atom;
[0279] Z is hydrogen or -S-alkyl;
[0280] R 1 and R 3 Each independently represents an alkyl or alkylene group -SO 3 - M + ;
[0281] R 2 and R 4 represents independently at each occurrence methyl, ethyl or propyl;
[0282] R 5 represents independently at each occurrence hydrogen, methyl, ethyl or propyl; and
[0283] M is a monovalent cation or is absent.
[0284] In certain embodiments, X 1 In certain embodiments, X2 is -S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 In certain embodiments, X 1 and X 2 Yes-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 .
[0285] In certain embodiments, the substituted heterocyclic group containing two tetravalent ring nitrogen atoms is a 5-6 membered saturated heterocyclic ring containing two tetravalent ring nitrogen atoms, wherein the ring is substituted by 1, 2 or 3 independently selected from alkyl, alkylene-C(O)NH 2 In certain embodiments, the substituted heterocyclic group containing one tetravalent ring nitrogen atom is a 5-6 membered aromatic heterocyclic ring containing one tetravalent ring nitrogen atom, wherein the ring is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkylene-C(O)NH 2 In some embodiments, the substituted heterocyclic group containing two tetravalent ring nitrogen atoms is one of the following:
[0286]
[0287] In certain embodiments, Y is one of the following: (a) ψ-CH 2 -C(O)N(H)-phenyl-(C 1 -C 4 )alkylene-; or (b)ψ-(CH 2 CH2 -O) 2-4 -CH 2 CH 2 -C(O)N(H)-(C 1 -C 2 )alkylene-C(O)N(H)-phenyl-(C 1 -C 4 In certain embodiments, Y is one of the following:
[0288]
[0289] In certain embodiments, R 1 It is alkylene -SO 3 - M + In certain embodiments, R 3 In certain embodiments, R 1 and R 3 It is alkylene -SO 3 - M + In certain embodiments, R 1 and R 3 Yes-(CH 2 ) 3 -SO 3 - M + In certain embodiments, R 2 In certain embodiments, R 4 In some embodiments, Z is hydrogen. In some embodiments, M is absent.
[0290] In certain embodiments, A is alkyl-CO 2 - In certain other embodiments, A is halogen, haloalkyl-CO 2 - , alkyl-SO 3 - or aryl-SO 3 - .
[0291] Another aspect of the present invention provides a compound represented by Formula VI or a salt thereof:
[0292]
[0293] in:
[0294] X 1 and X 2 Each independently represents hydrogen or one of the following groups, provided that X 1and X 2 Not all hydrogen:
[0295] (a)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic radical containing one tetravalent ring nitrogen atom)-A
[0296] (b)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 ;or
[0297] (c)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(C 1 -C 6 Alkylene)
[0298] n represents 1, 2, 3, or 4 independently at each occurrence;
[0299] A is a monovalent anion or is absent;
[0300] Y is one of the following:
[0301] (a)ψ-alkylene-C(O)N(R 5 )-arylene-alkylene-; or
[0302] (b)ψ-heteroalkylene-C(O)N(R 5 )-alkylene-C(O)N(R 5 )-arylene-alkylene-;
[0303] ψ is the bond to the amide nitrogen atom;
[0304] Z is hydrogen or -S-alkyl;
[0305] R 1 and R 3 Each independently represents an alkyl or alkylene group -SO 3 - M + ;
[0306] R 2and R 4 represents independently at each occurrence methyl, ethyl or propyl;
[0307] R 5 represents independently at each occurrence hydrogen, methyl, ethyl or propyl; and
[0308] M is a monovalent cation or is absent.
[0309] Another aspect of the present invention provides a compound represented by Formula VI or a salt thereof:
[0310]
[0311] in:
[0312] X 1 and X 2 Each independently represents hydrogen or one of the following groups, provided that X 1 and X 2 Not all hydrogen:
[0313] (a)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic radical containing one tetravalent ring nitrogen atom)-A
[0314] (b)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 ;or
[0315] (c)-S(O) 2 N(R 4 )-(C i -C 6 Alkylene)-C(O)N(R 5 )-Y-(C 1 -C 6 Alkylene)
[0316] n represents 1, 2, 3, or 4 independently at each occurrence;
[0317] A is a monovalent anion or is absent;
[0318] Y is one of the following:
[0319] (a)ψ-alkylene-C(O)N(R 5 )-arylene-alkylene-; or
[0320] (b)ψ-heteroalkylene-C(O)N(R 5 )-alkylene-C(O)N(R 5 )-arylene-alkylene-;
[0321] ψ is the bond to the amide nitrogen atom;
[0322] Z is hydrogen or alkyl;
[0323] R 1 and R 3 Each independently represents an alkyl or alkylene group -SO 3 - M + ;
[0324] R 2 and R 4 represents independently at each occurrence methyl, ethyl or propyl;
[0325] R 5 represents independently at each occurrence hydrogen, methyl, ethyl or propyl; and
[0326] M is a monovalent cation or is absent.
[0327] In certain embodiments, X 1 Yes-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 .
[0328] In certain embodiments, the substituted heterocyclic group containing two tetravalent ring nitrogen atoms is a 5-6 membered saturated heterocyclic ring containing two tetravalent ring nitrogen atoms, wherein the ring is substituted by 1, 2 or 3 independently selected from alkyl, alkylene-C(O)NH 2 In certain embodiments, the substituted heterocyclic group containing one tetravalent ring nitrogen atom is a 5-6 membered aromatic heterocyclic ring containing one tetravalent ring nitrogen atom, wherein the ring is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkylene-C(O)NH 2 In some embodiments, the substituted heterocyclic group containing two tetravalent ring nitrogen atoms is one of the following:
[0329]
[0330] In certain embodiments, wherein X 2 It's hydrogen.
[0331] In certain embodiments, Y is one of the following: (a) ψ-CH 2 -C(O)N(H)-phenyl-(C 1 -C 4 )alkylene-; or (b)ψ-(CH 2 CH 2 -O) 2-4 -CH 2 CH 2 -C(O)N(H)-(C 1 -C 2 )alkylene-C(O)N(H)-phenyl-(C 1 -C 4 In certain embodiments, Y is one of the following:
[0332]
[0333] In certain embodiments, R 1 In certain embodiments, R 3 It is alkylene -SO 3 - M + In certain embodiments, R 3 Yes-(CH 2 ) 3 -SO 3 - M + In certain embodiments, R 2 In certain embodiments, R 4 In some embodiments, Z is hydrogen. In some embodiments, M is absent.
[0334] In certain embodiments, A is alkyl-CO 2 - In certain other embodiments, A is halogen, haloalkyl-CO 2 - , alkyl-SO 3 - or aryl-SO 3 - .
[0335] In certain embodiments, the compound is the following compound or a salt thereof:
[0336]
[0337] Another aspect of the present invention provides a compound represented by formula VI-I or a salt thereof:
[0338]
[0339] in:
[0340] X 1 and X 2 Each independently represents hydrogen or one of the following groups, provided that X 1 and X 2 Not all hydrogen:
[0341] (a)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic radical containing one tetravalent ring nitrogen atom)-A
[0342] (b)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 ;or
[0343] (c)-S(O) 2 N(R 4 )-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(C 1 -C 6 Alkylene)
[0344] n represents 1, 2, 3, or 4 independently at each occurrence;
[0345] A is a monovalent anion or is absent;
[0346] Y is one of the following:
[0347] (a)ψ-alkylene-C(O)N(R 5 )-arylene-alkylene-; or
[0348] (b)ψ-heteroalkylene-C(O)N(R 5 )-alkylene-C(O)N(R 5 )-arylene-alkylene-;
[0349] ψ is the bond to the amide nitrogen atom;
[0350] Z is hydrogen or alkyl;
[0351] R 1 and R 3 Each independently represents an alkyl or alkylene group -SO 3 - M + ;
[0352] R 2 and R 4 represents independently at each occurrence methyl, ethyl or propyl;
[0353] R 5 represents independently at each occurrence hydrogen, methyl, ethyl or propyl; and
[0354] M is a monovalent cation or is absent.
[0355] Another aspect of the present invention provides a compound represented by Formula VII or a salt thereof:
[0356]
[0357] in:
[0358] X is one of the following:
[0359] (a)-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic radical containing one tetravalent ring nitrogen atom)-A
[0360] (b)-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 ;or
[0361] (c)-(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(C 1 -C 6 Alkylene)
[0362] n is 1, 2, 3, or 4;
[0363] A is a monovalent anion or is absent;
[0364] Y is one of the following:
[0365] (a)ψ-alkylene-C(O)N(R 5 )-arylene-alkylene-; or
[0366] (b)ψ-heteroalkylene-C(O)N(R 5 )-alkylene-C(O)N(R 5 )-arylene-alkylene-;
[0367] ψ is the bond to the amide nitrogen atom;
[0368] Z is an arylene group;
[0369] R 1 and R 3 Each independently represents an alkyl or alkylene group -SO 3 - M + ;
[0370] R 2 and R 4 represents independently at each occurrence methyl, ethyl or propyl;
[0371] R 5 represents independently at each occurrence hydrogen, methyl, ethyl or propyl; and
[0372] M is a monovalent cation or is absent.
[0373] In certain embodiments, X is -(C 1 -C 6 Alkylene)-C(O)N(R 5 )-Y-(substituted heterocyclic group containing two tetravalent ring nitrogen atoms)-(A) 2 .
[0374] In certain embodiments, the substituted heterocyclyl group containing two tetravalent ring nitrogen atoms is one of the following:
[0375]
[0376] In certain embodiments, Y is ψ-CH 2 -C(O)N(H)-phenyl-(C 1 -C 4 )alkylene-.
[0377] In certain embodiments, Y is one of the following:
[0378]
[0379] In certain embodiments, Z is
[0380] In certain embodiments, R1 In certain embodiments, R 3 It is alkylene -SO 3 - M + In certain embodiments, R 3 Yes-(CH 2 ) 3 -SO 3 - M + In certain embodiments, R 2 In certain embodiments, R 4 In certain embodiments, M is absent.
[0381] In certain embodiments, A is alkyl-CO 2 - In certain other embodiments, A is halogen, haloalkyl-CO 2 - , alkyl-SO 3 - or aryl-SO 3 - .
[0382] In certain embodiments, the compound is one of the following or a salt thereof:
[0383]
[0384] H. Specific Exemplary Bacterial Targeting Agents
[0385] Useful bacterial targeting agents can be produced using standard chemical means known in the art using one or more bacterial targeting components, imaging reporters, biomodifiers and linkers described above. Depending on the specific application, the bacterial targeting agent can be designed to be water-soluble or water-dispersible (i.e., sufficiently soluble or suspendable in aqueous or physiological medium solutions). The bacterial targeting agent preferably does not have any unwanted phototoxic properties and / or exhibits low serum protein binding affinity. Specific exemplary bacterial targeting agents are listed in Table 4. In some embodiments, the bacterial targeting agent is a bacterial targeting agent listed in Table 4 or a salt thereof.
[0386] Table 4
[0387]
[0388]
[0389]
[0390]
[0391] The imaging agents disclosed herein can be formulated into pharmaceutical compositions suitable for administration to a subject, such as an animal and / or a human.The pharmaceutical composition can include one or more imaging agents and one or more excipients, such as stabilizers, in a physiologically relevant carrier.
[0392] For in vivo use, the compositions of the present invention can be provided in a formulation suitable for administration to a subject, such as an animal or a human being. Thus, the formulation includes the agent together with a physiologically relevant carrier suitable for the desired form of administration and / or dosage. The term "physiologically relevant carrier" is understood to mean a carrier in which the agent is dispersed, dissolved, suspended, mixed, and physiologically tolerable, i.e., can be administered to, in or on the subject's body without excessive discomfort or irritation or toxicity. The preferred carrier is a fluid, preferably a liquid, more preferably an aqueous solution; however, carriers for solid formulations, topical formulations, inhalation formulations, ophthalmic formulations, and transdermal formulations are also contemplated within the scope of the present invention.
[0393] It is contemplated that the agent can be administered orally or parenterally. For parenteral administration, the agent can be injected intravenously, intramuscularly, dermally, transdermally, subcutaneously, rectally, nasally, vaginally, and ophthalmically. Thus, the composition can take the form of, for example, solid tablets, capsules, pills, powders including lyophilized powders, colloidal suspensions, microspheres, liposome particles, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, irrigation solutions, drenches, osmotic delivery devices, suppositories, enemas, injections, implants, sprays, or aerosols. Pharmaceutical compositions can be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A. R. Germaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
[0394] It should be understood that the formulation of the agent, the selection of the administration route, the dosage of the agent administered to the subject, and the timing between the administration of the agent and imaging are all within the skill of those skilled in the art.
[0395] II. Application
[0396] It will be appreciated that bacterial targeting agents can be used in a variety of imaging and therapeutic applications.
[0397] A. General Imaging Methods
[0398] The present invention provides methods for in vitro and in vivo imaging using the imaging agents disclosed herein. For a review of optical imaging techniques, see, for example, Alfano et al., Ann. NY Acad. Sci. 820:248-270 (1997); Weissleder, Nature Biotechnology 19, 316-317 (2001); Ntziachristos et al., Eur. Radiol. 13:195-208 (2003); Graves et al., Curr. Mol. Med. 4:419-430 (2004); Citrin et al., Expert Rev. Anticancer Ther. 4:857-864 (2004); Ntziachristos, Ann. Rev. Biomed. Eng. 8:1-33 (2006); Koo et al., Cell Oncol. 28:127-139 (2006); and Rao et al., Curr. Opin. Biotechnol. 18:17-25 (2007).
[0399] Optical imaging includes all methods from direct visualization without any device and using computer-based hardware such as various scopes, catheters and optical imaging equipment, such as for tomographic presentation. Imaging agents can be used in optical imaging modes and measurement techniques, including but not limited to: endoscopy, fluorescence endoscopy, luminescence imaging, time-resolved transmission imaging, transmission imaging, nonlinear microscopy, confocal imaging, acoustic-optical imaging, photoacoustic imaging, reflectance spectroscopy, spectroscopy, coherence interferometry, interferometry, optical coherence tomography, diffuse optical tomography and fluorescence-mediated molecular tomography (continuous wave, time-domain frequency-domain systems and early photons), as well as measurements of light scattering, absorption, polarization, luminescence, fluorescence lifetime, quantum yield and quenching.
[0400] Imaging systems useful in the practice of the present invention generally include three basic components: (1) a suitable light source for inducing excitation of the imaging agent, (2) a system for separating or resolving the emission from the light used for fluorophore excitation, and (3) a detection system. The detection system can be hand-held or incorporated into other useful imaging devices such as intraoperative microscopes. Exemplary detection systems include endoscopes, catheters, tomography systems, hand-held imaging systems, or intraoperative microscopes.
[0401] Preferably, the light source provides monochromatic (or substantially monochromatic) light. The light source can be appropriately filtered white light, i.e., bandpass light from a broad spectrum light source. For example, light from a 150 watt halogen lamp can be passed through a suitable bandpass filter commercially available from Omega Optical (Brattleboro, VT). Depending on the system, the light source can be a laser. See, e.g., Boas et al., Proc. Natl. Acad. Sci. USA 91:4887-4891, 1994; Ntziachristos et al., Proc. Natl. Acad. Sci. USA 97:2767-2772, 2000; and Alexander, J. Clin. Laser Med. Surg. 9:416-418, 1991. Information about lasers used for imaging can be found, e.g., at Imaging Diagnostic Systems, Inc., Plantation, FL, and various other sources. High pass or band pass filters can be used to separate the optical emission from the excitation light. Suitable high pass or band pass filters are commercially available from Omega Optical, Burlington, VT.
[0402] In general, the light detection system can be viewed as including a light collecting / image forming component and a light / signal detection / image recording component. The light collecting / image forming component and the light detection / image recording component are discussed separately, although the light detection system can be a single integrated device incorporating both components.
[0403] Particularly useful light focusing / image forming components are endoscopes. They have been used for a number of tissues and organs including the peritoneum (Gahlen et al., J. Photochem. Photobiol. B 52:131-135, 1999), ovarian cancer (Major et al., Gynecol. Oncol. 66:122-132, 1997), colon and rectum (Mycek et al., Gastrointest. Endosc. 48:390-394, 1998; and Stepp et al., Endoscopy 30:379-386, 1998), bile duct (Izuishi et al., Hepatogastroenterology 46:804-807, 1999), stomach (Abe et al., Endoscopy 50:115-116, 1998), and ureteral carcinoma (Crock et al., Endoscopy 51:116-117, 1999). Endoscopic devices and techniques for in vivo optical imaging of the lungs (Hirsch et al., Clin Cancer Res 7:5-220, 2001), brain (Ward, J. Laser Appl. 10:224-228, 1998), esophagus, and head and neck may be used in the practice of the present invention.
[0404] Other types of light focusing assemblies are catheter-based devices, including fiber optic devices. Such devices are particularly suitable for intravascular imaging. See, for example, Tearney et al., Science 276:2037-2039, 1997 and Circulation 94:3013, 1996.
[0405] Still other imaging techniques include phased array technology (Boas et al., Proc. Natl. Acad. Sci. USA 91:4887-4891, 1994; Chance, Ann. NY Acad. Sci. 838:29-45, 1998), optical tomography (Cheng et al., Optics Express 3:118-123, 1998; and Siegel et al., Optics Express 4:287-298, 1999), intravital microscopy (Dellian et al., Br. J. Cancer 82:1513-1518, 2000; Monsky et al., Cancer Res. 59:4129-4135, 1999; and Fukumura et al., Cell 94:715-725, 1998), confocal imaging (Korlach et al., Proc. Natl. Acad. Sci. USA 96:8461-8466,1999; Rajadhyaksha et al., J. Invest. Dermatol. 104:946-952,1995; and Gonzalez et al., J. Med. 30:337-356,1999) and fluorescence molecular tomography (FMT) (Nziachristos et al., Nature Medicine 8:757-760,2002, U.S. Patent No. 6,615,063, PCT WO 03 / 102558 and PCT WO 03 / 079015) can be used with the imaging agents of the present invention. Similarly, the imaging agents can be used in a variety of different imaging systems, such as (1) Imaging systems: 100 series, 200 series (Xenogen, Alameda, CA), (2) SPECTRUM and LUMINA (Xenogen, Alameda, CA), (3) or eXplore Optix TM (GE Healthcare, United Kingdom), (4) Maestro TM and Nuance TM-2 system (CRi, Woburn, MA), (5) Image Station In-Vivo FX from Carestream Molecular Imaging, Rochester, NY (formerly Kodak Molecular Imaging Systems), (6) OV100, IV100 (Olympus Corporation, Japan), (7) Cellvizio (Mauna Kea Technologies, France), (8) NanoSPECT / CT or HiSPECT (Bioscan, Washington, DC), (9) or LILA TM (Imaging Diagnostic Systems, Plantation, FL), (10) DYNOT TM (NIRx Medical Technologies, Glen Head, NY), and (11) NightOWL imaging system manufactured by Berthold Technologies, Germany.
[0406] Various light detection / image recording components, such as a charge coupled device (CCD) system or a photographic film, can be used in such a system. The choice of light detection / image recording depends on a variety of factors, including the type of light collecting / image forming components used. However, it should be understood that the selection of suitable components, their assembly into an optical imaging system, and the operation of the system are within the ordinary skill of the art.
[0407] For agents with magnetic properties, MRI imaging, which is well known in the art, can also be applied to the practice of the present invention. For a review of MRI technology, see Westbrook, Handbook of MRI Technique, 2nd edition, 1999, Blackwell Science. It is possible that images obtained by, for example, optical imaging and magnetic resonance imaging can be co-registered or fused to each other to provide additional information about the object to be imaged. In addition, multimodal imaging systems (i.e., combined optical and MR imaging systems) can be used to produce combined optical MR images.
[0408] In addition, the compositions and methods of the present invention can be used for other imaging compositions and methods. For example, the agents of the present invention can be imaged by other imaging modalities such as X-ray, computed tomography (CT), MR imaging, ultrasound, positron emission tomography (PET) and single photon computed tomography (SPECT).
[0409] In addition, the compositions and methods of the present invention can be used in combination with other imaging compositions and methods. For example, the reagent of the present invention can be imaged individually or in combination with other traditional imaging modes by optical imaging schemes, such as X-rays, computed tomography (CT), MR imaging, ultrasound, positron emission tomography (PET) and single photon computed tomography (SPECT). For example, the compositions and methods of the present invention can be used in combination with CT or MRI to obtain both anatomical and molecular information, such as by being annotated with an image produced by another imaging mode. The compositions and methods of the present invention can also be used in combination with X-rays, CT, PET, ultrasound, SPECT and other optical and MR contrast agents, or the reagent of the present invention can also include imaging agents such as iodine, gadolinium atoms and radioactive isotopes, which can be detected using the combination of CT, PET, SPECT and MR imaging modes with optical imaging. Imaging agents can be connected to or incorporated into reagents.
[0410] (i) In vivo imaging methods
[0411] For in vivo optical imaging, such methods include (a) administering one or more bacteria targeting agents described herein to a subject, (b) providing sufficient time for the agent to be distributed in the subject, and (c) detecting a signal emitted by the bacteria targeting agent. The signal emitted by the agent can be used to construct an image, such as a tomographic image. The above steps can be repeated at predetermined time intervals, thereby allowing the emission signal of the bacteria targeting agent to be evaluated over time in the subject.
[0412] In another in vivo imaging method, the method includes (a) administering to a subject one or more bacterial targeting agents containing fluorescent dyes described herein; (b) providing sufficient time for the bacterial targeting agent to be distributed in the subject; (c) exposing the subject to light of a wavelength that can be absorbed by the fluorescent dye; and (d) detecting a signal emitted by the bacterial targeting agent. The above steps can be repeated at predetermined time intervals, thereby allowing the emission signal of the bacterial targeting agent to be evaluated over time in the subject. The irradiation and / or detection steps (steps (c) and (d) respectively) can be performed using an endoscope, a catheter, a tomography system, a planar system, a handheld imaging system, goggles, or an intraoperative microscope.
[0413] Before or during these steps, a detection system can be located around or near a subject (e.g., an animal or human) to detect signals emitted from the subject. The emitted signals can be processed to construct an image, such as a tomographic image. In addition, the processed signals can be displayed as separate images or fused (combined) images.
[0414] In addition, an in vivo imaging method can be practiced simultaneously, which selectively detects and images one, two or more molecular imaging probes including bacterial targeting agents. In such a method, for example, in the above-mentioned step (a), two or more imaging probes whose signal properties can be distinguished from each other are administered to the subject simultaneously or successively, wherein at least one molecular imaging probe is a bacterial targeting agent. The use of multiple probes allows recording of multiple biological processes, functions or targets.
[0415] The subject may be a vertebrate, such as a mammal, such as a human being. The subject may also be a non-vertebrate used for laboratory research (such as Caenorhabditis elegans, Drosophila or other model organisms for research, etc.).
[0416] The information provided by such in vivo imaging methods, such as the presence, absence or level of an emitted signal, can be used to detect and / or monitor disease in a subject. Exemplary diseases include, but are not limited to, autoimmune diseases, bone diseases, cancer, cardiovascular diseases, environmental diseases, skin diseases, immune diseases, genetic diseases, infectious diseases, metabolic diseases, neurodegenerative diseases, ophthalmic diseases, and respiratory diseases. In addition, in vivo imaging can be used to evaluate the effect of a compound or therapy by using an imaging agent, wherein a subject is imaged before and after treatment with the compound or therapy, and the corresponding signals / images are compared.
[0417] Bacterial targeting agents can also be used for in vivo imaging methods in which cells labeled with bacterial targeting agents are administered to a subject. Cells can be labeled with bacterial targeting agents in vivo or in vitro. In the in vitro method, cells can be directly derived from the subject or derived from other sources (e.g., from other subjects, cell cultures, etc.). Bacterial targeting agents can be mixed with cells to effectively label cells, and the resulting labeled cells are administered to the subject in step (a). Steps (b)-(d) are then performed as described above. This method can be used to monitor the transport and positioning of certain cell types including T-cells, tumor cells, immune cells and stem cells, as well as other cell types. In particular, this method can be used to monitor cell-based therapies.
[0418] It is understood that the formulation of the bacteria targeting agent, the selection of the administration route, the dosage of the bacteria targeting agent administered to a subject, and the timing between the administration of the bacteria targeting agent and imaging are within the skill level of those skilled in the art.
[0419] The above methods can be used to determine a variety of markers, including tracking the localization of bacterial targeting agents in a subject over time, or evaluating changes or alterations in the metabolism and / or excretion of bacterial targeting agents in a subject over time. By imaging the molecular events and biological pathways modulated by therapies for such diseases, the methods can also be used to track such therapies, including but not limited to determining efficacy, optimal timing, optimal dosage levels (including for individual patients or trial subjects), and synergistic effects of therapeutic combinations.
[0420] The methods and compositions of the present invention can be used to help doctors or surgeons identify and characterize areas of disease, such as infection and cell death, to distinguish diseased and / or infected tissue from normal tissue, such as detecting specific bacterial infection areas within an organ or other tissue that are difficult to detect using conventional imaging techniques, and further evaluate the tissue as a candidate for a specific treatment modality, or to assess the likelihood of a prognosis such as sepsis. In addition, the methods and compositions can be used to image sites that undergo increased apoptosis, as indicated by endogenous non-infected cells having an increased positively charged cell surface.
[0421] The methods and compositions of the present invention can also be used for the detection, characterization and / or location determination of a disease, including early stage disease, severity of a disease or disease-related condition, stage of a disease and / or monitoring a disease. The presence, absence or level of an emitted signal can indicate a disease state.
[0422] The methods and compositions of the present invention can also be used to monitor and / or guide various therapeutic interventions such as surgical procedures, and to monitor drug therapies, including cell-based therapies. The methods described herein can also be used to assess the efficacy of various treatment modalities, including but not limited to those designed to reduce tumor acidosis and metastasis or various radiotherapies. The methods of the present invention can also be used for the prognosis of a disease or disease condition.
[0423] For each of the above, examples of such diseases or disease conditions that can be detected or monitored (before, during or after therapy) include inflammation (e.g., inflammation caused by arthritis, such as rheumatoid arthritis), cancer (e.g., colorectal, ovarian, lung, breast, prostate, cervical, testicular, skin, brain, gastrointestinal, pancreatic, liver, kidney, bladder, stomach, leukemia, oral, esophageal and bone cancer), cardiovascular disease (e.g., atherosclerosis and inflammatory disorders of the blood vessels, ischemia, stroke, thrombosis and disseminated intravascular coagulation), skin diseases (e.g., Kaposi's sarcoma, psoriasis and atopic dermatitis), ophthalmic diseases (e.g., macular degeneration and diabetic retinopathy), infectious diseases (e.g., bacterial, viral, fungal and parasitic infections, including acquired immunodeficiency syndrome, malaria, trypanosomiasis and schistosomiasis), immune diseases (e.g. autoimmune disorders, lymphoma, multiple sclerosis, rheumatoid arthritis, diabetes, lupus erythematosus, myasthenia gravis and Graves' disease), central nervous system diseases (e.g. neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis and prion diseases), genetic diseases, metabolic diseases, environmental diseases (e.g. poisoning by lead, mercury and radioactive substances, and skin cancer), bone-related diseases (e.g. osteoporosis, primary and metastatic bone tumors and osteoarthritis), neurodegenerative diseases and surgery-related complications (e.g. graft rejection, organ rejection, altered wound healing, fibrosis or other complications associated with surgical implants).
[0424] Therefore, the methods and compositions described herein can be used, for example, to detect and / or quantify the presence and / or location of cell surfaces with increased positive charge in subjects, such as humans, such as infected or apoptotic cells, and to detect and / or quantify the presence and / or location of infection and cell death, including the presence of infection or apoptotic areas in organs. The methods and compositions described herein can also be used to detect and / or quantify bacteria and apoptosis associated with diseases, disorders and conditions, including but not limited to pre-tumor / tumor diseases, including areas at risk of acute occlusion (i.e. vulnerable plaques) in coronary and peripheral arteries, areas of aneurysmal enlargement, unstable plaques in carotid arteries, and ischemic areas. The methods and compositions of the present invention can also be used for the identification and assessment of cell death, injury, apoptosis, necrosis, and tissue hypoxia. The methods and compositions can also be used for drug release and monitoring of drug release, particularly when drugs or drug-like molecules are chemically linked to fluorescent probes. Exemplary drug molecules include chemotherapeutic agents and cell growth inhibitors and photodynamic agents, including but not limited to Photofrin, Lutrin, Antrin, aminolevulinic acid, hypericin, benzoporphyrin derivatives, and porphyrins.
[0425] In addition, the methods and compositions described herein can be used for imaging bacterial infections in subjects. The method includes administering to a subject (e.g., a human or animal) one or more bacterial targeting agents described herein in an amount sufficient to promote bacterial imaging. After a sufficient time has passed to allow the reagent to be distributed in the animal or distributed in the area to be imaged, the presence and / or amount of the reagent is determined. The presence and / or amount of the reagent can then be used to generate an image of the cell surface representing an increase in positive charge in the subject's tissue, such as a tomographic image.
[0426] In addition, the methods and compositions described herein can be used to image bacterial infections in a subject, such as tuberculosis, Lyme disease, brucellosis, pertussis, pneumonia, tetanus, diphtheria, typhoid fever, meningitis, cellulitis, impetigo, botulism, psittacosis, urethritis, enteritis, colitis, anthrax, Legionnaires' disease, syphilis, tularemia, bronchitis, ulcers, sores, leptospirosis, listeriosis, gonorrhea, shigellosis, salmonellosis, cholera, cystitis, sepsis, toxinoses, endocarditis, necrotizing pneumonia, toxic shock syndrome, scarlet fever, rheumatic fever, necrotizing fasciitis, and Rocky Mountain spotted fever.
[0427] (ii) In vitro imaging methods
[0428] For in vitro imaging, imaging agents can be used in various in vitro assays. For example, an exemplary in vitro imaging method includes: (a) contacting a sample, such as a biological sample, with one or more bacterial targeting agents described herein; (b) allowing the agent to interact with a biological target in the sample; (c) optionally, removing unbound agent; and (d) detecting a signal emitted from the agent to determine whether the agent has been activated by or bound to the biological target. When the bacterial targeting agent comprises a fluorescent dye, step (d) further comprises irradiating the sample with light of a wavelength that can be absorbed by the fluorescent dye to produce an emission signal.
[0429] After the reagent has been designed, synthesized and optionally formulated, it can be tested in vitro by those skilled in the art to evaluate its biology and performance characteristics. For example, different types of cells grown in culture medium can be used to evaluate the biology and performance characteristics of the reagent. The cellular uptake, combination or cellular localization of the reagent can be evaluated using techniques known in the art including, for example, fluorescence microscopy, FACS analysis, immunohistochemistry, immunoprecipitation, in situ hybridization and Forster resonance energy transfer (FRET) or fluorescence resonance energy transfer. For example, the reagent can be contacted with the sample for a period of time and then cleaned to remove any free reagent. Then a suitable detection device can be used, such as a fluorescence microscope equipped with a suitable filter that matches the optical properties of the fluorescent reagent to observe the sample. Fluorescence microscopy or scintillation counting of cells in culture are also conventional means for determining whether intake and combination occur. Samples such as cell centrifugation samples of tissues, tissue sections and other types can also be used in a similar manner to evaluate the biology and performance characteristics of the reagent. Other detection methods can also be used, including but not limited to flow cytometry, immunoassay, hybridization assay and microarray analysis.
[0430] B. Exemplary Imaging Methods
[0431] One aspect of the invention provides an in vivo imaging method comprising: (a) administering a compound described herein (e.g., a bacterial imaging agent) to a subject; (b) allowing the agent to distribute in the subject; and (c) detecting a signal emitted by the bacterial imaging agent.
[0432] Another aspect of the invention provides a method for in vivo optical imaging, comprising: (a) administering to a subject a compound described herein (e.g., a bacterial imaging agent), wherein the agent comprises a fluorescent dye; (b) allowing the agent to distribute in the subject; (c) exposing the subject to light of a wavelength that can be absorbed by the fluorescent dye; and (d) detecting a signal emitted by the agent.
[0433] Another aspect of the present invention provides an in vivo imaging method, wherein the signal emitted by the agent is used to construct an image. In other embodiments, the image is a tomographic image. In certain embodiments, the present invention is an in vivo optical imaging method, wherein steps (a)-(c) are repeated at predetermined time intervals, thereby allowing the emission signal of the bacterial targeting agent to be evaluated in the subject over time. In certain embodiments, the present invention is an in vivo optical imaging method, and steps (a)-(d) are repeated at predetermined time intervals, thereby allowing the emission signal of the bacterial targeting agent to be evaluated in the subject over time. In certain embodiments, the present invention is an in vivo imaging method, wherein the subject is an animal or a human. In certain embodiments, the present invention is an in vivo imaging method, wherein in step (a), two or more imaging probes whose signal properties can be distinguished from each other are administered to the subject, wherein at least one of the imaging probes is a bacterial targeting agent. In certain embodiments, the present invention is an in vivo optical imaging method, wherein the irradiation and detection steps are performed using an endoscope, a catheter, a tomography system, a handheld optical imaging system, or an intraoperative microscope.
[0434] Another aspect of the invention provides an in vivo imaging method, wherein the presence, absence or level of the emission signal is indicative of a disease state. In certain embodiments, the invention is an in vivo imaging method, wherein the method is used to detect and / or monitor a disease. In certain embodiments, the disease is selected from bone disease, cancer, cardiovascular disease, environmental disease, skin disease, immune disease, genetic disease, infectious disease, inflammatory disease, metabolic disease, ophthalmic disease and respiratory disease.
[0435] Another aspect of the present invention provides an in vivo imaging method, wherein in step (a), cells labeled with a compound described herein (eg, a bacterial targeting agent) are administered to the subject. In other embodiments, the signal emitted by the agent is used to monitor the transport and positioning of cells.
[0436] Another aspect of the invention provides a method for imaging a bacterial infection in a subject, the method comprising the steps of: (a) administering an agent to the subject; and (b) detecting the presence of the agent, thereby generating an image representative of the bacterial infection. In certain embodiments, the invention is a method of treating a disease in a subject, the method comprising administering an agent systemically or locally to the subject, wherein the agent comprises a radioactive marker that localizes in the disease area and emits an effective dose of radiation.
[0437] Another aspect of the present invention provides an in vitro imaging method, the method comprising: (a) contacting a sample with a reagent; (b) allowing the reagent to bind to a biological target; (c) optionally removing unbound reagent; and (d) detecting a signal emitted from the reagent to thereby determine whether the reagent has been activated or bound by the biological target. In other embodiments, the sample is a biological sample.
[0438] In certain embodiments, the chemical modification group comprises a bioactive molecule, such as a drug or radiotherapy moiety. In certain embodiments, the bioactive molecule is connected to the agent via a linker, which can be cleaved by biological or physical mechanisms including, but not limited to, enzymatic, thermal, acid-catalyzed, or photochemical cleavage.
[0439] In certain preferred embodiments, Q can be selected from (i) substituted or unsubstituted aryl, (ii) functionalized substituted or unsubstituted heteroaryl, (iii) functionalized substituted or unsubstituted C 1 -C 18 In other embodiments, Q is absent.
[0440] In certain embodiments, the chemically modified moiety M increases the binding selectivity of the bacteria targeting agent to negatively charged bacterial and apoptotic cell surfaces compared to other negatively charged endogenous cell surfaces.
[0441] In certain embodiments, the chemically modified moiety M reduces the non-specific cell membrane permeability of the bacterial targeting agent. In addition, in other embodiments, the chemically modified moiety M reduces the non-specific tissue accumulation of the bacterial targeting agent when administered to a living animal.
[0442] In one aspect of the invention, the bacterial targeting agent fluoresces in the far-red or near-infrared spectral range.
[0443] In certain embodiments, the bacteria targeting agent further comprises one or more chemical modifiers independently chemically linked to DABCO, L and / or F or any combination thereof.
[0444] C. Therapeutic Applications
[0445] Certain bacteria targeting agents described herein, such as agents containing radioactive markers and drug molecules, can be used to improve the symptoms of a specific disease or disorder or to treat a specific disease or disorder. The method includes (a) administering one or more agents described herein in an amount sufficient to provide a therapeutic effect in vivo in a subject; and (b) providing enough time to allow the agent to be distributed in vivo in the subject or otherwise positioned in the subject area to be treated, and then (c) depending on the therapeutic agent, optionally activating the agent to provide a therapeutic effect. For example, when the therapeutic agent is a radioactive marker, no subsequent activation is required. However, when the therapeutic agent is a photoreactive agent such as a dye used in photodynamic therapy, the agent can be activated by exposing the agent to light with a wavelength that activates the agent. As a result, the agent can be used to treat target conditions, such as cancer, immune disorders, inflammatory disorders, vascular disorders, etc. In addition, the agent can be used to inhibit infection in an organ or other target area in vivo in a subject, or to reduce the proliferation of bacteria and apoptotic cells in the subject.
[0446] The present invention will now be illustrated by means of the following examples, which are provided for illustrative purposes only and are not intended in any way to limit the scope of the present invention.
[0447] III. Pharmaceutical Compositions
[0448] The agents described herein can be formulated with one or more pharmaceutically acceptable carriers (additives) and / or diluents to obtain a pharmaceutical composition. An exemplary pharmaceutical composition comprises one or more agents and one or more pharmaceutically acceptable carriers. As described in detail below, the pharmaceutical composition can be specially formulated for administration in solid or liquid form, including forms suitable for the following administration: (1) oral administration, such as an immersion (aqueous or non-aqueous solution or suspension), tablets such as tablets intended for buccal, sublingual and systemic absorption, pills, powders, granules, pastes for application to the tongue; (2) parenteral administration, such as by subcutaneous, intramuscular, intravenous or epidural injection, as, for example, a sterile solution or suspension or a sustained release formulation; (3) topical administration, such as a cream, ointment or controlled release patch or spray applied to the skin; (4) intravaginal or rectal, such as a suppository, cream or foam; (5) sublingual administration; (6) ocular administration; (7) transdermal administration; or (8) nasal administration.
[0449] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0450] Pharmaceutically acceptable carriers include liquid or solid fillers, diluents, excipients, manufacturing aids (e.g., lubricants, talc, magnesium, calcium or zinc stearate, or stearic acid), or solvent encapsulating agents, which are involved in carrying or transporting the target compound from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols. (11) polyols, such as propylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; and (22) other nontoxic compatible substances used in pharmaceutical formulations.
[0451] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0452] Pharmaceutical compositions of the invention suitable for parenteral administration comprise a combination of one or more agents of the invention and one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or comprise sterile powders that can be reconstituted in sterile injectable solutions or dispersions immediately before use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.
[0453] In certain embodiments, the present invention provides a pharmaceutically acceptable composition suitable for administration to a subject, comprising a bacteria imaging agent and a pharmaceutically acceptable excipient.
[0454] IV. Definitions
[0455] To facilitate understanding of the present invention, a number of terms and phrases are defined below.
[0456] As used herein, references without a specific number mean "one or more" and include the plural unless the context does not require otherwise.
[0457] As used herein, the term "effective amount" refers to an amount of a compound sufficient to achieve a beneficial or desired result. Unless otherwise stated, an effective amount may be administered in one or more administrations, applications or dosages, and is not intended to be limited to a particular formulation or route of administration. As used herein, the term "treatment" includes any effect that causes improvement in a condition, disease, disorder, etc., or improvement in its symptoms, such as relief, alleviation, regulation, improvement or elimination.
[0458] When used herein, the terms "patient" and "subject" refer to an organism to be subjected to the methods of the present invention or treated with the subject. Such organisms include, but are not limited to, mammals (e.g., mice, monkeys, horses, cows, pigs, dogs, cats, etc.), and most preferably humans.
[0459] Certain compounds described herein may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds falling within the scope of the present invention, including cis and trans isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof. Other asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in the present invention.
[0460] As used herein, the term "affinity" refers to the ability of a bacteria targeting agent to bind to and / or be retained by negatively charged cells.
[0461] As used herein, the term "functional group" is understood to refer to a reactive functional group that can be further modified or derivatized by other molecules. In one aspect, the reactive functional group is an amine, carboxylic acid, carboxylate, halogen, hydrazine, hydroxylamine, nitrile, isonitrile, isocyanate, isothiocyanate, thiol, maleimide, azide, alkyne, tetrazolyl, phosphonate, olefin, nitro or nitroso.
[0462] The term "alkyl" is well known in the art and includes saturated aliphatic groups, including straight-chain alkyl and branched alkyl. In addition, the term "alkyl" (or "low alkyl") includes "substituted alkyl", which refers to an alkyl component having a substituent replacing the hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acyl), thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphoryl, phosphonate, phosphinate, amino, aminoacyl, amidine, imino, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, aralkyl or aromatic or heteroaromatic components. It will be appreciated by those skilled in the art that the components substituted on the hydrocarbon chain can themselves be substituted if appropriate. For example, substituents of substituted alkyl groups may include substituted and unsubstituted forms of amino, azido, imino, aminoacyl, phosphoryl (including phosphonates and phosphinates), sulfonyl (including sulfates, sulfonamides, sulfamoyls and sulfonates), and silyl, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylic acids and esters), -CN, etc. In certain embodiments, the alkyl group is unsubstituted.
[0463] The term "alkylene" refers to a divalent radical of an alkyl group. Exemplary alkylene groups include -CH 2 -and-CH 2 CH 2 .
[0464] The term "heteroalkyl" is well known in the art and refers to a saturated aliphatic group, including straight chain alkyl and branched chain alkyl, in which one backbone carbon atom has been replaced by a heteroatom such as O, S or N. Exemplary heteroalkyl groups include -CH 2 -O-CH 3 and -CH 2 CH 2 -O-CH 3 .
[0465] The term "heteroalkylene" refers to a divalent radical of a heteroalkyl group. Exemplary heteroalkylene groups include -CH 2 -O-CH 2 -and-CH 2 CH 2 -O-CH 2 -.
[0466] The term "aryl" is well known in the art and refers to 5, 6 and 7-membered monocyclic aromatic groups, which may include 0 to 4 heteroatoms, such as benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, etc. The aryl having heteroatoms in the ring structure may also be referred to as "heteroaryl" or "heteroaromatic". The aromatic ring may be substituted at one or more ring positions by substituents as described above, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, aminoacyl, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclic, aromatic or heteroaromatic components, -CF3, -CN, etc. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbon atoms are common to two adjacent rings (the rings are "fused rings"), wherein at least one of the rings is aromatic, the other cyclic rings being, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and / or heterocyclyl.
[0467] As used herein, the term "arylene" refers to a divalent radical of an aromatic group. Arylene groups may be optionally substituted as described for aryl groups or as otherwise indicated. Exemplary arylene groups are
[0468] As used herein, the terms "heterocycle" and "heterocyclyl" refer to aromatic or non-aromatic rings containing one or more heteroatoms. The heteroatoms may be the same or different from each other. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, and sulfur. Aromatic and non-aromatic heterocycles are well known in the art. Some non-limiting examples of aromatic heterocycles include pyridine, pyrimidine, indole, purine, quinoline, and isoquinoline. Non-limiting examples of non-aromatic heterocyclic compounds include piperidine, piperazine, morpholine, pyrrolidine, and pyrazolidine. Examples of oxygen-containing heterocycles include, but are not limited to, furan, ethylene oxide, 2H-pyran, 4H-pyran, 2H-chromene, and benzofuran. Examples of sulfur-containing heterocycles include, but are not limited to, thiophene, benzothiophene, and parathiazine. Examples of nitrogen-containing rings include, but are not limited to, pyrrole, pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazoline, imidazolidine, pyridine, piperidine, pyrazine, piperazine, pyrimidine, indole, purine, benzimidazole, quinoline, isoquinoline, triazole and triazine. Examples of heterocyclic rings containing two different heteroatoms include, but are not limited to, phenothiazine, morpholine, parathiazine, oxazine, oxazole, thiazine and thiazole. The ring of the heterocyclic ring (or heterocyclic group) is optionally further replaced by, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, aminoacyl, carboxylic acid, -C (O) alkyl, -CO ... 2Alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, aryl or heteroaryl moiety, -CF 3 , -CN, etc.
[0469] The terms "amine" and "amino" are well known in the art and refer to both unsubstituted and substituted amines, such as moieties represented by the following general formula:
[0470]
[0471] Where R 50 , R 51 , R 52 and R 53 Each independently represents hydrogen, alkyl, alkenyl, -(CH 2 ) m -R 61 , or R 50 and R 51 Together with the N atoms to which they are attached, they complete a heterocyclic ring having 4 to 8 atoms in the ring structure; R 61 represents aryl, cycloalkyl, cycloalkenyl, heterocyclic or polycyclic; and m is 0 or an integer in the range of 1 to 8. In certain embodiments, R 50 or R 51 Only one of them can be a carbonyl group, for example R 50 , R 51 In other embodiments, R 50 and R 51 (and optionally R 52 ) each independently represents hydrogen, alkyl, alkenyl or -(CH 2 ) m -R 61 .
[0472] The term "alkoxyl" or "alkoxy" is well known in the art and refers to an alkyl group as defined above to which an oxygen group is bonded, representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy, etc. "Ether" is two hydrocarbons covalently linked by oxygen. Thus, the substituent of an alkyl group that makes the alkyl group an ether is or is similar to an alkoxy group, for example, it can be -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(CH 2 ) m -R 61 Indicates that m and R 61 Defined above.
[0473] The term "substituted" refers to that one or more hydrogen atoms in a group are independently replaced by the same or different substituents. Exemplary substituents include, but are not limited to, halogen, alkyl, haloalkyl, oxy, alkoxy, sulfhydryl, thioether, cyano, ester, ketone, amide, sulfonamide, carboxylate, carboxylic acid, aryl, aralkyl, alkenyl, alkynyl, alkylene-amide groups, etc.
[0474] When used in this article, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention, which, after being administered to a subject, can provide a compound of the present invention or its active metabolite or residue. As known to those skilled in the art, the "salt" of a compound of the present invention can be derived from an inorganic or organic acid and base. Examples of acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, p-toluenesulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, ethanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, etc. Other acids, such as oxalic acid, although not pharmaceutically acceptable per se, can be used in the preparation of salts that can be used as intermediates in obtaining compounds of the present invention and pharmaceutically acceptable acid addition salts thereof.
[0475] Examples of bases include, but are not limited to, alkali metal (eg, sodium) hydroxides, alkaline earth metal (eg, magnesium), hydroxides, ammonia, and compounds of formula NW 4 + The compound wherein W is C 1-4 Alkyl, etc.
[0476] Examples of salts include, but are not limited to, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, fluoroheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmitate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and the like. Other examples of salts include pyrophosphate, ... + NH 4 + and NW 4 + (W is C 1-4 The anion of the compound of the present invention which is combined with an alkyl group or the like.
[0477] For therapeutic use, it is contemplated that the salts of the compounds of the invention are pharmaceutically acceptable. However, salts of acids and bases that are not pharmaceutically acceptable may also find use, for example, in the preparation or purification of pharmaceutically acceptable compounds.
[0478] Throughout this specification, when compositions and kits are described as having, including, or comprising specific components, or when processes and methods are described as having, including, or comprising specific steps, it is also contemplated that there are additional compositions and kits of the invention that consist essentially of or consist of the recited components, and that there are processes and methods of the invention that consist essentially of or consist of the recited process steps.
[0479] V. Examples
[0480] The compounds of the present invention can be synthesized from readily available starting materials according to standard methods and procedures. The following non-limiting examples demonstrate the synthesis of exemplary fluorescent bacterial targeting agents. Representative materials and methods that can be used to prepare the materials of the present invention are further described below. Unless otherwise stated, all chemicals and solvents (reagent grade) are used in their commercially available state without further purification. The synthesized compounds are characterized and purified by HPLC.
[0481] The synthesis of the binding components is shown in the reaction scheme below.
[0482]
[0483] Intermediate 1. To a solution of Boc-glycine (770 mg, 4.4 mmol), 4-aminophenethanol (550 mg, 4.0 mmol), NEM (90 μL) in 20 mL of acetonitrile was added O-(2-oxy-1(2H)pyridinyl)-N,N,N',N'tetramethylurea tetrafluoroborate (1.28 g, 4.4 mmol).
[0484] After 4 hours, the solution was concentrated to 0.5 mL and ethyl acetate (15 mL) was added, followed by 8 mL of 0.1 M NaHCO 3 The organic layer was washed with 5 mL of 0.1 M NaHCO 3 The mixture was then washed with 2 x 5 mL of deionized water. Evaporation to dryness gave the product 1 as an off-white solid.
[0485] Intermediate 2. To a suspension of 1 (120 mg, 0.4 mmol) in 3 mL of anhydrous MeCN was added TEA (130 μL, 0.93 mmol), and the mixture was cooled in an ice bath. A solution of methanesulfonyl chloride (MsCl, 48 μL, 0.62 mmol) in 1.5 mL of anhydrous MeCN (1.5 mL) was added slowly over 5 min, and after addition the mixture was warmed to ~20 °C and aged for 1 hour. The MeCN was removed by speedvac, and the residue was extracted between 8 mL of ethyl acetate and 2 mL of 0.05 N HCl aqueous solution. The organic layer was washed with 2 mL of deionized water and 2x2 mL of saturated brine. In anhydrous Na 2 SO 4 After drying on ice, the solution was evaporated to dryness to obtain 2 as a solid.
[0486] Intermediate 3. DABCO (45 mg, 400 μmol) was added to a solution of 2 (50 mg, 134 μmol) in 1 mL MeCN, and the mixture was heated at ~60-70 ° C for 6-8 hours. The solution was concentrated to a thick oil by speedvac and dissolved in 1.5 mL 1:9 MeCN / TEAA buffer (25 mM HOAc, 12.5 mM TEA). The crude product was not completely dissolved, but it could be loaded onto the resin as is. After loading onto a short column (~4 mL bed volume) of phenyl resin, the resin was eluted with 10 mL TEAA, collected as F-1, and then eluted with 10 mL 5:95 MeCN / TEAA (F-2), 10 mL 10:90 MeCN / TEAA (F-3), 10 mL 15:85 MeCN / TEAA (F-4) and 10 mL 20 / 80 MeCN / TEAA (F-5). The fractions were analyzed by HPLC, and F-2 and F-3 were combined and concentrated to dryness.
[0487] Intermediate 4. Intermediate 3 (53 mg, 118 μmol) was dissolved in 1 mL DMF, and iodomethane (25 μL, 400 μmol) was added. The solution was aged for 40 minutes at 20 ° C. The solution was concentrated to dryness. The solid was dissolved in 3 mL DMF and divided into two parts (2 and 1 mL in a glass test tube). Evaporated to dryness, 4 (70 mg and 29 mg, respectively) was obtained as a colloidal solid.
[0488] Intermediate 5. TFA (400 μL) was added to a test tube containing 70 mg of 4 (70 w%, 83 μmol), the mixture was mixed and aged at 20 °C for 20 minutes. The colloidal solid became a suspension during the reaction. The mixture was diluted with 1 mL of MeCN and dried by speedvac without heating for ~20 minutes. The product was washed with 3x2 mL of MTBE by ultrasound / centrifugation and dried without heating for 10 minutes. The solid was dissolved in 1.9 mL of 0.1 N NaHCO containing 100 μL of DMSO. 3 in aqueous solution and immediately used to react with fluorophore-active esters.
[0489] Intermediate 6. Intermediate 3 (50 mg, 110 μmol) was dissolved in 1 mL DMF and 2-chloroacetamide (22 mg, 236 μmol) was added. The solution was heated at 70 ° C for 16 hours. The solution was diluted with 3 mL acetonitrile and the product was precipitated. The solid was washed with 3x2 mL acetonitrile and dried under vacuum.
[0490] Intermediate 7. TFA (400 μL) was added to a test tube containing 70 mg of 6 (20 mg), the mixture was mixed and aged at 20°C for 20 minutes. The gummy solid became a suspension during the reaction. The mixture was diluted with 1 mL of MeCN and dried by speedvac without heating for ~20 minutes. The product was washed with 3x2 mL of MTBE by ultrasound / centrifugation and dried without heating for 10 minutes. The solid was dissolved in 1.9 mL of 0.1 N NaHCO containing 100 μL of DMSO. 3 in aqueous solution and immediately used to react with fluorophore-active esters.
[0491] Synthesis of bacteria targeting agents
[0492] Method 1. To a solution of DABCO-Me or DABCO-amide (~20 μmol) in 1 mL of 0.1 M sodium bicarbonate aqueous solution was added a solution of fluorophore NHS ester (~4 μmol) in 1 mL of DMSO. After 30 minutes, the solution was diluted with water and the product was isolated by loading the solution onto a phenyl resin (2 g) and eluting with a gradient of a mixed triethylamine acetate aqueous solution (triethylamine: 12.5 mM, acetic acid: 25 mM) and acetonitrile (containing 12.5 mM TEA and 25 mM acetic acid, 10 / 90-50 / 50). ~5 mL of the fraction was collected and analyzed by HPLC.
[0493] Method 2. To a solution of fluorophore (~4 μmol) and DABCO-Me or DABCO-amide (40 μmol) in 1:1 DMF / water (1 mL) containing 20 μL N-ethylmorpholine was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate (20 μmol). After 2 hours, the solution was diluted with 5 mL of water and loaded onto 2 g of phenyl resin. The resin was eluted with a gradient of a mixed triethylamine acetate aqueous solution (triethylamine: 12.5 mM, acetic acid: 25 mM) and acetonitrile (containing 12.5 mM TEA and 25 mM acetic acid, 10 / 90-30 / 70).
[0494] Example 1: Synthesis of Exemplary Compound 3-((E)-2-((2E,4E,6E)-7-(5-(N-(4-((2-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-1,3,3-trimethyl-3H-indol-1-ium-2-yl)hept-2,4,6-trien-1-ylidene)-3,3-dimethylindolin-1-yl)propane-1-sulfonate diacetate - Compound A1:
[0495]
[0496] Compound A1 was prepared using Method 1. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0497] Example 2: Synthesis of Exemplary Compound 3-((E)-2-((2E,4Z,6E)-7-(5-(N-(4-((2-((4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-1,3,3-trimethyl-3H-indol-1-ium-2-yl)-4-(methylthio)hept-2,4,6-trien-1-ylidene)-3,3-dimethylindolin-1-yl)propane-1-sulfonate diacetate - Compound A2
[0498]
[0499] Compound A2 was prepared using Method 1. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0500] Example 3: Synthesis of exemplary compound 1-(2-amino-2-oxoethyl)-4-(4-(2-(4-(N,1,3,3-tetramethyl-2-((1E,3E,5E,7E)-7-(1,3,3-trimethylindolin-2-ylidene)hept-1,3,5-trien-1-yl)-3H-indol-1-ium-5-sulfonamido)butanyl)ethanoyl)phenethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diodium triacetate - Compound A3:
[0501]
[0502] Compound A3 was prepared using Method 1. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0503] Example 4: Synthesis of Exemplary Compound 3-(2-((1E,3Z,5E)-3-(5-((6-((2-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-6-oxohexyl)carbamoyl)pyridin-2-yl)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)propane-1-sulfonate diacetate - Compound A4:
[0504]
[0505] Compound A4 was prepared using Method 2. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0506] Example 5: Synthesis of exemplary compound 3-(3,3-dimethyl-5-(N-methyl-N-(4-((2-((4-(2-(4-methyl-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)sulfamoyl)-2-((1E,3E,5E,7E)-7-(1,3,3-trimethylindolin-2-ylidene)hept-1,3,5-trien-1-yl)-3H-indol-1-ium-1-yl)propane-1-sulfonate diacetate - Compound A5:
[0507]
[0508] Compound A5 was prepared using Method 1. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0509] Example 6: Synthesis of Exemplary Compound 3-(3,3-dimethyl-2-((E)-(3-((E)-(1,3,3-trimethyl-5-(N-methyl-N-(4-((2-((4-(2-(4-methyl-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)sulfamoyl)indol-2-ylidene)methyl)cyclopent-2-en-1-ylidene)methyl)-3H-indol-1-ium-1-yl)propane-1-sulfonate diacetate - Compound A6:
[0510]
[0511] Compound A6 was prepared using Method 1. Fractions with >95% @ 650 nm were combined and dried to a solid.
[0512] Example 7: Synthesis of Exemplary Compound 3-(3,3-dimethyl-2-((1E,3Z,5E)-3-(5-((6-((2-((4-(2-(4-methyl-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-6-oxohexyl)carbamoyl)pyridin-2-yl)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium-1-yl)propane-1-sulfonate diacetate - Compound A7:
[0513]
[0514] Compound A7 was prepared using Method 1. Fractions with >95% @ 635 nm were combined and dried to a solid.
[0515] Example 8: Exemplary Compounds 3-(5-(N-(4-((2-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-2-((1E,3E,5E,7E)-7-(5-(N-(4-((2-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-2-((1E,3E,5E,7E)-7-(5-(N-(4-((2-((4-(2-(4-(2-amino (2-(2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-3,3-dimethyl-1-(3-sulphanoylpropyl)indolin-2-ylidene)hept-1,3,5-trien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)propane-1-sulfonate triacetate - Synthesis of Compound A8:
[0516]
[0517] Compound A8 was prepared using Method 2. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0518] Example 9: Exemplary Compounds 3-((E)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(N-methyl-N-(4-((2-((4-(2-(4-methyl-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)sulfamoyl)-1-(3-sulphonylpropyl)-3H-indole-1 Synthesis of 1-(4-((2-((4-(2-(4-methyl-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)sulfamoyl)indolin-1-yl)propane-1-sulfonate triacetate - Compound A9:
[0519]
[0520] Compound A9 was prepared using Method 2. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0521] Example 10: Exemplary Compounds 3-(5-(N-(4-((2-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-2-((1E,3E,5E)-5-(5-(N-(4-((2-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-2-((1E,3E,5E)-5-(5-(N-(4-((2-((4-(2-(4-(2-amino (2-(2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-N-methylsulfamoyl)-3,3-dimethyl-1-(3-sulphanoylpropyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)propane-1-sulfonate triacetate - Synthesis of Compound A10:
[0522]
[0523] Compound A10 was prepared using Method 2. Fractions with >95% @ 635 nm were combined and dried to a solid.
[0524] Example 11: Exemplary Compounds 3-((E)-2-((2E,4E)-5-(3,3-dimethyl-5-(N-methyl-N-(4-((2-((4-(2-(4-methyl-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)sulfamoyl)-1-(3-sulphonylpropyl)-3H-indole-1- Synthesis of Compound A11:
[0525]
[0526] Compound A11 was prepared using Method 2. Fractions with >95% @ 635 nm were combined and dried to a solid.
[0527] Example 12: Synthesis of exemplary compound 3-(5-(N-(1-((4-(2-(4-(2-amino-2-oxoethyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diol-1-yl)ethyl)phenyl)amino)-1,4,17-trioxy-7,10,13-trioxa-3,16-diazaeicosan-20-yl)-N-methylsulfamoyl)-3,3-dimethyl-2-((1E,3E,5E,7E)-7-(1,3,3-trimethylindolin-2-ylidene)hept-1,3,5-trien-1-yl)-3H-indol-1-ium-1-yl)propane-1-sulfonate diacetate - Compound A12:
[0528]
[0529] Compound A12 was prepared using Method 1. Fractions with >95% @ 750 nm were combined and dried to a solid.
[0530] Example 13 - Bacteria Targeting Agent Binding to Bacteria in Vitro
[0531] This example demonstrates that the bacterial targeting agents described herein bind to various bacterial species in vitro. The bacteria were grown at 37°C to an OD of 600=0.3-0.5, and centrifuged at 3500 rpm for 4 minutes, and then the resulting pellet was resuspended in TES buffer. Bacteria with or without targeting agents were grown under the same conditions. The bacterial targeting agent compound A7 was incubated with the bacterial pellet in TES buffer at a final concentration of 10 μM for 1 hour at room temperature. Figure 1A As seen in , bacteria containing the reagents were centrifuged, resuspended in TES buffer and analyzed by flow cytometry.
[0532] In this experiment, fluorescence was associated only with bacteria in the presence of the bacterial targeting agents described herein. Figure 1B Shown is a bar graph comparing the mean fluorescence between bacteria alone and bacteria incubated with the exemplary bacteria targeting agent Compound A7. Figure 1A and 1B As shown in , the results demonstrate in vitro binding of a bacteria targeting agent such as Compound A7 to both Escherichia coli and Staphylococcus epidermidis.
[0533] Example 14 - In vivo imaging of Staphylococcus epidermidis using bacterial imaging agents
[0534] Use 10 8 CFU (colony forming units) of Staphylococcus epidermidis were injected intramuscularly into the left thigh of 6-8 week old SKH1-E female mice. Approximately 24 hours after the initial bacterial inoculation, mice were intravenously injected with 5 nM of the bacterial targeting agent Compound A7. As in Figure 2A As seen in , mice were imaged on a FMT2500 (PerkinElmer, Inc., Waltham, MA) at time points 1, 2, and 3 hours after agent injection, with emphasis on the thigh. Figure 2B As shown, statistically significant differences between infected and uninfected areas were observed at all time points, with the optimal imaging time being at the 1 hour time point.
[0535] Example 15 - In vivo imaging of Escherichia coli using bacterial imaging agents
[0536] Use 10 5 -10 8Different concentrations of Escherichia coli (CFU) were injected intramuscularly into the left thigh of 6-8 week old SKH1-E female mice. About 24 hours after the initial bacterial inoculation, the mice were intravenously injected with 5 nM of the bacterial targeting agent Compound A7. Figure 3 As seen in , mice were imaged on a FMT2500 (PerkinElmer, Inc., Waltham, MA) 1 hour after agent injection, with focus on the thigh. The image shows significant uptake of the bacterial targeting agent at the site of infection.
[0537] Incorporated by Reference
[0538] All publications, patents, and patent applications cited herein are expressly incorporated by reference in their entirety and for all purposes to the same extent as if each were so individually indicated.
[0539] Equivalence
[0540] The present invention may be embodied in other specific forms without departing from its spirit and essential characteristics. Therefore, the above embodiments are considered in all respects to be illustrative rather than limiting the invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the preceding description, and it is intended that all changes within the meaning and equivalent scope of the claims be included therein.
Claims
1. Use of the following reagent or its salt for preparing bacteria-targeting products
